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1. INTRODUCTION 
1.1 CYTOLOGY OF THE ANTERIOR PITUITARY LOBE AND PHYSIOLOGY OF 
GONADOTROPIN SECRETION. 
1.1.1 Function and cytology of the anterior pituitary lobe. 
The pituitary gland, surrounded by the spenoid bone and 
covered with the sellar diaphragm, lies in the sella turcica, 
near the hypothalamus and optic chiasm. The anterior pituitary 
lobe, which constitutes the major part of the pituitary gland, 
produces various hormones: growth hormone (GH), prolactin (PRL), 
adenocorticotroph hormone (ACTH), thyroid stimulating hormone 
(TSH), follicle stimulating hormone (FSH) and luteinizing hormone 
(LH). 
Based on light microscopy, the glandular cells of the 
adenohypophysis can be divided in three types: chromophobe, 
acidophilic and basophilic cells, which represent, approximately, 
50, 40 and 10% of the total number of cells. The chromophilic, 
i.e. acidophilic and basophilic, cells contain secretory granules 
which have great affinity for specific dyes, while the chromopho-
be cells do not contain visible secretory granules when inves-
tigated by light microscopy. On electron microscopic examination, 
however, the majority of chromophobe cells can be shown to have 
small secretory granules, and therefore these cells should also 
be regarded as active glandular cells (1). 
Immunocytochemistry allows a more sophisticated classification 
of secretory cells. Hormone-specific antibodies that bind 
intracellularly to the hormone to be studied are applied to the 
pituitary tissue. Thereafter, the tissue is incubated with a 
second antibody coupled to peroxidase, and finally the tissue is 
incubated in 3,3'-diaminoazobenzidine which forms a brown 
precipitate in the sites that contain the hormone. Thus, it is 
possible to classify cells according to the hormones they 
contain. The frequency distribution of secretory cells according 
to immunocytochemistry is given in figure 1. It is presumed that 
each cell-type contains only one hormone, with the exception of 
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cells that contain the gonadotropins LH and FSH. Though some of 
these cells may contain either of the gonadotropins {3,4), the 
current view is that almost all gonadotroph cells contain both 
LH and FSH (2,5). It should be noticed, however, that the 
presence of more than one hormone is not limited to gonadotroph 
cells, as cells that contain both GH and PRL have been demonstra-
ted. recently {6). Therefore, the percentages given in figure 1 
should be regarded as rough estimates. 
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Figure 1: Frequency distribution of secretory cells in the 
anterior pituitary according to immuncytochemistry. (From: 
Kovacs K et al.: Anatomy and histology of the normal and 
abnormal pituitary gland (2)) 
1.1.2 Structure and physiology of the gonadotropins. 
The gonadotropins LH and FSH have a molecular weight of 
approximately 30.000 and are composed of an a- and a B-subunit, 
just like TSH and the placental hormone chorionic gonadotropin 
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(CG). The a-subunits of these glycoprotein hormones are identi-
cal, while the B-subunits are hormone-specific (7,8). The inter-
species similarity in a number of animals is greatest for the B-
subunits, while the a-subunits may differ widely (9). 
The hypothalamic hormone gonadotropin releasing hormone (GnRH) 
or luteinizing hormone releasing hormone (LHRH) reaches the 
pituitary by route of hypothalamic hypophyseal portal system. It 
stimulates the production and release of the gonadotropins. The 
release of GnRH is influenced by opioids and mono-amines, whereas 
steroids can influence the release of these two substances {10). 
In both sexes, the release of gonadotropins is influenced by 
the circulating levels of the steroids of which they promote the 
production. In men testosterone inhibits the release of LH (11), 
while in women estrogens may exert both positive and negative 
feedback on LH release, depending on the serum concentrations of 
these steroids during the menstrual cycle. Testosterone in men 
and estradiol in women also suppress FSH release, but the gonadal 
hormone inhibin is thought to be more important in regulating FSH 
levels (12). Apart from a direct effect on the pituitary 
gonadotroph, estradiol and testosteron are thought to affect the 
opioid control of GnRH release (10,13). 
In both sexes the gonadotropins stimulate the release of 
steroids by their target organs. In men LH stimulates the 
production of testosterone in the testicular interstitial cells, 
while in women LH stimulates the ovarian producion of progestins, 
androgens and estrogens. In men FSH, through its effect on the 
Sertoli cells, has a role in the control of spermatogenesis (14). 
In women FSH, through its action on the ovarian granulosa cells 
promotes follicle growth and stimulates the synthesis of 
estradiol from androgens (15). 
1.1.3 Dynamic tests of gonadotropin release in normal 
subjects. 
Administration of GnRH results in a rise in serum gonadotro-
pins and free a-subunit, both in men and in women (16,17). 
Administration of TRH to normal men has been reported to cause 
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slight increases in LH or FSH levels. The reported results, 
however, are contradictory, as some groups report an increase in 
LH but not FSH levels (18,19), while others report the opposite 
(20,21). 
The opiate antagonist naloxone causes a rise in serum 
gonadotropin concentrations in men and premenopausal women. This 
is due to the antagonizing effect of this drug on the inhibitory 
action of opioids on GnRH release (10,13,22). 
Administration of estradiol in women and of testosterone in 
men causes a decrease in serum gonadotropin and a-subunit levels 
(11,23-26). 
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1.2 PITUITARY NONFUNCTIONING AND GONADOTROPH ADENOMAS. 
1.2.1 Prevalence and presenting symptoms. 
Pituitary adenomas are benign neoplasms arising in the 
adenohypophyseal cells. Pituitary adenomas can be classified 
according to several characteristics: according to the clinical 
presentation (1), to the hormones hypersecreted in vivo (2), to 
the chromophilia of the tumor tissue (3), or to the immunocyto-
chemical properties of the tumor tissue ( 4) • The second and 
fourth classification are the ones most commonly used, the 
classification based on elevated serum hormone concentrations 
being pre-operative, the classification based on tumor im-
munocytochemistry being post-operative. 
In figure 2 the prevalence of various types of pituitary 
adenomas in large series of surgically removed pituitary tumors 
is shown. The adenomas are classified according to the im-
munocytochemical properties of the tissue. 
When one compares figure 2 with figure 1, which lists the 
frequencies of secretory cells according to immunocytochemistry 
in the normal pituitary, a marked infrequency of adenomas that 
contain one of the glycoprotein hormones, LH, FSH or TSH, can be 
noticed. Like PRL secreting cells, glycoprotein hormone secreting 
cells account for about 15% of the secretory cells of the 
anterior pituitary (figure 1). However, PRL secreting adenomas 
represent 25-30% and glycoprotein hormone secreting adenomas less 
than 5% of all operated adenomas. 
Based on elevated serum gonadotropin concentrations, the 
gonadotroph cell adenomas are rarely encountered: they account 
for 1.7 to 3.3% of the total of surgically removed pituitary 
adenomas (29,30). Almost all patients who are clinically 
recognized as having a gonadotroph adenoma are men (29-56; for 
reviews see 40,57). In virtually all patients serum FSH levels 
are elevated and frequently serum a-subunit concentrations are 
also high. Hypersecretion of LH is seldomly described and may 
in a substantial number of reported cases be ascribed to elevated 
levels of uncombined gonadotropin subunits which crossreact in 
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the LH radioimmunoassay (RIA) (40). 
Pure a-subunit secreting pituitary adenomas have also been 
reported predominantly in men (51,55,58-62). Though it is 
questionable whether these adenomas can be regarded gonadotroph 
adenomas, some of these tumors have been shown to secrete 
gonaaotropins when cultured (63) (see Chapter 1.2.5). 
Clinically nonfunctioning adenomas do not cause any signs or 
symptoms related to the hypersecretion of a pituitary hormone. 
They are characterized by the absence of hypersecretion of any 
pituitary hormone in vivo. 
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Figure 2: Prevalence of pituitary adenomas classified 
according to immunocytochemistry in large series of surgically 
removed tumors. In the group of nonfunctioning adenomas no or 
very few hormone positive cells could be detected. Except for 
adenomas that contain both gonadotropins, plurihormonal 
adenomas have not been listed. (From: Kovacs et al. (27) and 
Wilson et al. (28)) 
Patients with a gonadotroph, a-subunit secreting or clinically 
nonfunctioning pituitary adenoma have several clinical charac-
teristics in common: 
-They are elderly people. From the literature, the mean age 
of the patients can be estimated to be 50 to 60 years in all 
three patient groups (30-34,36,37,39,41-56,58-61,64-66). 
-Unlike most patients with a GH or PRL producing adenoma, 
these patients have no symptoms caused by overproduction of a 
hormone. 
-Almost all patients have macroadenomas with suprasellar 
extension. Symptoms caused by local pressure of the tumor tissue, 
i.e. visual field defects, loss of visual acuity and headache, 
are present in the majority of cases. Loss of libido and 
impotence in men and sudden amenorrhoea in women are also 
frequent. Hypopituitarism may be present (28,29,31-37,40,43,44, 
57,58,60,67-69). 
1.2.2 Etiology. 
The cause of gonadotroph, a~subunit secreting and clinically 
nonfunctioning pituitary adenomas is unknown. There are, however, 
indications that support the hypothesis that primary hypogonadism 
might play a role in the development of these tumors: 
-A high incidence of pituitary gonadotroph cell like adenomas 
can be found 15 months or more after gonadectomy in both male and 
female rats (70). 
-In some patients with a gonadotroph adenoma, castration or 
ovarian ablation had been performed decades before the pituitary 
tumor was'diagnosed (52,71,72). 
-Gonadotroph, a-subunit secreting, and clinically nonfunctio-
ning pituitary adenomas occur in elderly patients. Apart from 
adenomas that cause symptoms, subclinical pituitary adenomas 
which do not give rise to any endocrinological abnormalities or 
complaints have been found in 13% of the cases at unselected 
autopsies of men and women over 80 years of age. About 50% of 
these tumors have no immunocytochemical activity (73). In both 
normal men and women, sex steroids are low in aging as compared 
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to young subjects. In men there is an age-dependent decrease in 
serum free testosterone concentrations and a moderate increase 
in serum gonadotropin levels (7 4) , while in elderly, postmenopau-
sal, women estrogen concentrations are low and serum gonadotropin 
levels are high. 
on the other hand, the majority of patients with a gonado-
troph, clinically nonfunctioning or a-subunit secreting adenoma 
have a history of normal gonadal function and have children. In 
most men with such pituitary adenomas, a significant rise in 
serum testosterone in response to CG is noted (75), while in 
premenopausal patients ovarian estradiol production may be normal 
or become normal after therapy (54), indicating that primary 
defects in the gonads do not play a role. Also, in aging men a 
moderate age-associated decrease in serum free testosterone 
concentrations occurs (74), while in postmenopausal women serum 
estrogen concentrations are dramatically low in comparison with 
those in premenopausal women. If hypogonadism were an etiological 
factor in the development of gonadotroph, a-subunit secreting and 
clinically non-functioning pituitary adenomas, the incidence of 
these tumors should be higher in women than in men. However, no 
sex-related difference in the incidence of these tumors exists. 
Lastly, a hypothalamic cause of these tumors, in particular 
changes in GnRH pulse frequency or amplitude, should be consi-
dered. In ovariectomized monkeys bearing hypothalamic lesions a 
GnRH pulse given every hour restores the release of LH and FSH. 
Higher frequencies reduce the release of gonadotropins whereas 
lower frequencies lead to a rise in FSH levels only (76). In men 
with idiopathic hypogonadotropic hypogonadism, a reduction in the 
pulse frequency of administered GnRH leads to increased serum FSH 
concentrations (77). In the majority of patients with a gonado-
troph pituitary adenoma serum FSH concentrations are high whereas 
LH levels are not elevated. In patients with a clinically 
nonfunctioning pituitary adenoma serum gonadotropin concentra-
tions may be low (see Chapter 1. 2. 4) • If serum gonadotropin 
concentrations in these patients were caused by abnormalities in 
the GnRH pulse frequency, GnRH pulse frequency might be expected 
to be low in patients with a gonadotroph pituitary adenoma, and 
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high in patients with a clinically nonfunctioning pituitary 
tumor. 
In conclusion, whether gonadotroph, a-subunit secreting and 
clinically nonfunctioning adenomas are caused by mild or overt 
hypogonadism, remains unclear. Also, it is uncertain whether 
these tumors are caused by primary pituitary or primary hypotha-
lamic abnormalities (40). 
1.2.3 Morphology. 
Most gonadotroph adenomas are chromophobic on light micro-
scopic examination, and some may in part be basophilic. The cells 
are arranged in a sinusoidal pattern (47). 
Immunocytochemistry reveals in most of the tumors cells that 
are positive for FSH, a-subunit or, less frequently, LH. In 
women, tumors that have the ultrastructural features of gonado-
troph adenomas, do not immunostain in about 50% of the cases (47, 
see below). 
On electron microscopic examination, most gonadotroph adenomas 
can be shown to consist of elongated cells with small nuclei. The 
Rough Endoplasmatic Reticulum (RER) can be moderately or well 
developed·, and may form cisternae. Numerous free ribosomes may 
be observed. Small secretory granules measuring 50-250 nm vary 
in number from cell to cell and from tumor to tumor. A striking 
feature of the cytoplasm is the abundance of microtubules 
(30,47). Oncocytic transformation of the cells, i.e. an abundance 
of mitochondria, may be observed in a number of cases (30). 
Horvath and Kovacs (47) noted a difference in the fine structure 
of gonadotroph cell adenomas from women compared to those from 
men: a honey-comb like Golgi apparatus could be observed in the 
adenomas from women. The functional relevance of this observation 
is not clear. It should also be noticed that only 1 of 15 women 
with a gonadotroph adenoma described by these authors had 
documented elevated serum gonadotropin concentrations, and that 
their definition of these adenomas depends largely on the 
immunocytochemical or ultrastructural features of the cells. 
Morphological data on pure a-subunit secreting adenomas are 
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scarce. Tumor material from patients with elevated serum a-
subunit concentrations immunostains for a-subunit, but not for 
the gonadotropins (58) • Ultrastructurally, this group of patients 
has not been described as a separate entity. 
Clinically nonfunctioning adenomas appear chromophobic on 
light microscopic examination. Their cells may be arranged in a 
sinusoidal or diffuse pattern. By immunocytochemistry, these 
adenomas are either negative for all pituitary hormones or they 
contain only a few scattered cells staining for the glycoprotein 
hormones. Alternatively, they may consist of cells reacting with 
antibodies to a-subunit (78, 79). Electron microscopy reveals 
tumors consisting of small cells with a poorly developed RER, 
clusters of free ribosomes and a variable number of small, rod-
shaped mitochondria. Secretory granules, measuring up to 250 nm, 
are scarce. oncocytic transformation may be noticed (80). 
1.2.4 In vivo hormone data and dynamic tests on gonadotropin 
release. 
Virtually all patients with a pituitary gonadotroph adenoma, 
as defined by elevated serum gonadotropin concentrations, are men 
(see 40,57 for reviews). Serum FSH concentrations are supranormal 
in the majority of cases, and can be accompanied by high levels 
of FSH.B or a-subunit. Elevated serum lli concentrations are 
reported infrequently and can often be ascribed to crossreaction 
of a-subunit in the lli immunoassay (30, 39,40, 43, 46). In some 
cases, however, reported lli levels are too high to be caused by 
a-subunit crossreactivity (54) or are accompanied by high 
testosterone levels (36,37,50). 
Pure a-subunit secreting pituitary adenomas, characterized 
by elevated serum concentrations of only a-subunit, have been 
described also chiefly in men (51,55,58-62). The infrequency of 
pure a-subunit secreting adenomas and gonadotroph adenomas in 
women may be due to the fact that most female patients are 
postmenopausal; the high normal values of the gonadotropins and 
a-subunit after the menopause will mask the secretion of these 
hormones by the tumor. 
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Clinically nonfunctioning pituitary adenomas are characterized 
by the absence of hypersecretion of any pituitary hormone in 
vivo. Serum LH, FSH and a-subunit concentrations may be within 
the normal range or may be low (45,55,64,69). 
Administration of GnRH to patients with a gonadotroph, a-
subunit secreting or clinically nonfunctioning adenoma may result 
in either a supranormal, normal or low response in serum gonado-
tropin and subunit concentrations (38,58-60,75, see Chapter 5). 
Administration of TRH to patients with a gonadotroph adenoma 
results in exaggerated responses in serum LH and FSH levels 
compared to normal subjects (18, see Chapter 5). 
Hormone responses to other substances will be discussed in 
Chapter 1. 2. 6. 
1.2.5 In vitro hormone data. 
Surgically removed pituitary tumor cells can be dispersed and 
cultured. Adenomas which cause elevated serum gonadotropin 
concentrations will release these glycoprotein hormones in vitro, 
while virtually no other hormones can be detected. In vivo and 
in vitro hormone responses to drugs and hormones are well 
correlated (36,40,63,81). 
The release of gonadotropins and their subunits from cultured 
gonadotroph adenoma cells can be stimulated by TRH and GnRH 
(39,43,53,71). The dopamine agonist bromocriptine can suppress 
the release of FSH, LH and their subunits to a variable extent 
( 43). 
Pituitary adenomas which cause elevated serum levels of only 
a-subunit, may release both a-subunit and FSH in vitro (63). 
In recent years, it has been reported that clinically 
nonfunctioning adenomas may release gonadotropins and their 
subunits in vitro (45,53,63,64,71,82). Compared to gonadotroph 
adenomas, clinically nonfunctioning adenomas release only small 
amounts of these hormones and subunits (63). Expression of one 
or more glycoprotein hormone genes (a-subunit, LHB, FSHB and 
TSHB) may be observed, while GH and PRL gene expression is absent 
(55). 
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1.2.6 Experimental treatments and therapy. 
Transsphenoidal surgery is the accepted treatment for 
gonadotroph, a-subunit secreting and clinically nonfunctioning 
pituitary adenomas. This may be followed by radiotherapy 
{28,35,58). Improvement of visual field defects after surgery 
is observed in the majority of cases (28,35,83), and peripheral 
concentrations of hormones or subunits that were hypersecreted 
preoperatively return to the normal range (35,58). During the 6-
week postoperative period, mortality in a large series was 0.4%, 
while major morbidity like cerebrospinal fluid leak and bacterial 
meningitis occurred in about 10% of the cases (28). 
The administration of bromocriptine can lower serum gonadotro-
pin and a-subunit concentrations in patients with a gonadotroph 
or a-subunit secreting tumor (31,33,41,43,50,62). Improvement of 
visual field defects in a patient with a gonadotroph adenoma 
after 1 week of bromocriptine treatment (7.5 mg daily) has been 
reported, though after 1 year of treatment no change in tumor 
size could be demonstrated by Computed Tomographic (CT) scan 
(41). In another patient with a gonadotroph adenoma 2 months of 
therapy with increasing doses of bromocriptine (from 7.5 to 20 
mg daily) resulted in a slight reduction in tumor mass by CT scan 
(50). Recently, Klibanski et al. (62) reported a decrease in 
tumor size in 2 of 4 patients with an a-subunit secreting 
pituitary tumor who were treated with bromocriptine up to 10 mg 
daily for 6 weeks. 
The administration of bromocriptine to patients with clinical-
ly nonfunctioning adenomas by several researchers has led to 
conflicting results: Johnston et al. (66) reported a decrease in 
tumor size in a patient with a clinically nonfunctioning adenoma 
after 25 months of bromocriptine treatment (20 mg daily), while 
after 3 months no change in tumor size by CT scan could be shown. 
Wass et al. (84) also reported a reduction in tumor size in a 
patient treated with 7.5 mg bromocriptine daily for 4 months. On 
the other hand, Barrow et al. (85) did not note any reduction in 
tumor volume in 7 patients with a clinically nonfunctioning 
adenoma treated with 7.5 mg bromocriptine daily for 6 weeks, 
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while Grossman et aL (86) observed the same in 12 patients 
treated for 3 to 36 months (median: 6.5 months) with 3 different 
dopamine agonists. Lastly, Zarate et al. (87) found no ameliora-
tion of vision or tumor volume reduction in 7 patients treated 
for 2 to 23 weeks with bromocriptine in dosages of 15-22.5 mg 
daily. 
The administration of testosterone in men and estradiol in 
women with a gonadotroph adenoma lowers serum gonadotropin and 
a-subunit concentrations, but to a lesser extent than in normal 
subjects (34,54). No data on tumor volume after long-term 
treatment with steroids are available. 
In a patient with a gonadotroph adenoma, treatment with a 
GnRH analog for 3 weeks resulted in an increased secretion of 
LH and a-subunit (37). Recently, 2 groups reported on the effects 
of treatment for 8 to 9 weeks with these analogs in patients with 
a gonadotroph adenoma. The effects on serum LH and FSH concentra-
tions were variable, while serum a-subunit levels were higher 
than pretreatment values in all patients. No change in tumor 
volume after GnRH analog treatment could be demonstrated by CT 
scan in any patient (51,56). 
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2. AIMS AND SCOPE OF THE THESIS. 
This thesis deals with clinically nonfunctioning, ,a-subunit 
secreting and gonadotroph pituitary adenomas. From the litera-
ture discussed in the preceding chapter several questions arise. 
Below these questions are listed with a reference to where the 
subject concerned was mentioned or discussed in the preceding 
chapter, as well as with a reference to the chapter where these 
questions will be discussed in detail. 
1. (1.2.5) Do all clinically nonfunctioning pituitary adenomas 
release gonadotropins and their subunits in vitro? (4,5,6) 
2. (1.2.5) Can the hormone release from clinically non-
functioning adenomas in vitro be suppressed and stimulated with 
hormones and drugs? (5,6) 
3. ( 1. 2. 3, 1. 2. 5) Is the secretory activity of clinically 
nonfunctioning, a-subunit secreting, and gonadotroph adenomas 
better reflected in results from cell culture than in results 
from immunocytochemistry? (6) 
4. (1.2.1,1.2.5) Are clinically nonfunctioning, a-subunit 
secreting, and gonadotroph pituitary adenomas to be regarded as 
one group? (5,6) 
5. (1.2.4} Is the exaggerated response in serum gonadotropin 
levels to TRH limited to patients with a gonadotroph adenoma? (5) 
6. (1. 2. 6) can bromocriptine significantly suppress serum 
gonadotropin and a-subunit concentrations in patients with a 
clinically nonfunctioning adenoma and will these patients benefit 
from prolonged treatment with bromocriptine? (5,8) 
7. (1.1.2,1.2.2) By analogy with the findings in aging men, 
do serum estradiol concentrations decrease and gonadotropin 
levels increase in aging postmenopausal women? (7) 
8. (1.2.6) Can GnRH analogs be beneficial in patients with 
gonadotroph pituitary adenomas? (8) 
9. Which drugs are promising in the future treatment of 
gonadotroph, a-subunit secreting, and clinically nonfunctioning 
pituitary adenomas? (8) 
The major subjects discussed in the various chapters are 
listed below: 
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An introduction to the literature on clinically nonfunc-
tioning, a-subunit secreting and gonadotroph pituitary adenomas 
was given in Chapter 1. 
The presenting symptoms of these adenomas and some in vivo 
data are discussed in Chapter 3. 
confounding factors in the· in vitro research of these adenomas 
are analyzed in Chapter 4. 
The correlations between in vivo and in vitro hormone data, 
effects of TRH and bromocriptine, and similarities between 
gonadotroph and clinically nonfunctioning adenomas are dis-
cussed in Chapter 5. 
Additional in vitro data are presented in Chapter 6. 
The etiology of clinically nonfunctioning and gonadotroph 
adenomas is discussed in the light of the age-dependent changes 
in gonadotropin and sex steroid levels in normal subjects in 
Chapter 7. 
The role of 2 drugs that might be useful in the therapy of 
clinically nonfunctioning, a-subunit secreting and gonadotroph 
pituitary adenomas is discussed in Chapter a. 
A discussion of the major conclusions of this thesis is 
presented in Chapter 9. 
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3. THE CLINICAL PRESENTATION OF "NONFUNCTIONING" PJ[TUI:TARY 
ADENOMAS. 
Adapted from: Kwekkeboom DJ, Leunisse M, van der zwan L, de Jong 
FH, Lamberts SWJ. "Nonfunctioning" pituitary adenomas in vivo and 
in vitro. Advances in the Biosciences Vol. 69; Pergamon Press, 
oxford 1988;pp 417-20. 
ABSTRACT 
Thirtytwo patients with the clinical diagnosis "nonfunc-
tioning pituitary adenoma" were treated by transsphenoidal 
surgery. These were 20 men and 12 women; the mean age was 58 
years. Deteriorating vision was the most frequent initial 
complaint (n=20;63% of the patients). Circulating FSH and LH 
levels were low in 9 and normal in 2 women, while 16 men had 
high or normal and 2 had low values. However, 9 men had low 
testosterone (T) levels. High subunit levels may have accounted 
for the discrepancy between LH and T levels. 
INTRODUCTION 
Nonfunctioning adenomas of the pituitary are being called 
nonfunctioning because they do not cause any symptoms by 
overproduction of a hormone. Generally, patients present with 
loss of visual acuity andjor visual field defects (1,2), while 
hypersecretion of pituitary hormones seems absent. In recent 
years, however, hypersecretion of gonadotropins and gonadotropin 
subunits by nonfunctioning adenomas has been reported (for 
reviews see 3,4). Moreover, many clinically nonfunctioning 
adenomas have been reported to secrete LH, FSH or gonadotropin 
subunits in vitro (3-5). 
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PATIENTS AND METHODS 
Patients. To evaluate the in vivo presentation of nonfunc-
tioning adenomas, we studied a group of 32 patients, who were 
clinically diagnosed as having a "nonfunctioning" adenoma of the 
pituitary and who were treated by transsphenoidal surgery between 
1980 and 1986. There were 20 men and 12 women. The mean age was 
58 years. 
Primary complaints, i.e. complaints which, in retrospect, 
were noticed first, of patients were looked up in patient files, 
and, if necessary, additional information was obtained in retro-
spective interviews. 
Morphologic techniques applied to identify the removed tissue 
consisted of trichrome and PAS-stains as well as immunocytoche-
mistry with specific antibodies as previously described {5). 
Radioimmunoassays for GH, PRL, and ACTH were performed using 
commercial kits. Gonadotropins in serum were measured using 
polyclonal antibodies with 20-50% {U/U) crossreactivity for 
a-subunit and LHB. Standards used in these assays were: for LH 
MRC 68/40, and for FSH MRC 69/104. 
RESULTS 
In 32 patients who were clinically diagnosed as having a 
nonfunctioning adenoma of the pituitary, and in whom the 
diagnosis was confirmed by histologic examination of the removed 
tissue, sufficient data were available to evaluate the nature and 
duration of primary complaints. Deteriorating vision was the most 
frequent primary complaint; it was present in 20 patients {63%). 
Impotence or loss of libido was present in 9, headache in 7. As 
to the duration of the complaints, it is noteworthy that most of 
the patients {17/20) who sought advice because of worsening 
vision were treated within 2 years after the onset of their 
complaints, while in the group that had sexual complaints many 
{6/9) were treated only after 4 to 15 years. Most of the patients 
who had these latter complaints were men {8/9). 
Serum levels of LH and FSH were estimated in 29 patients. 
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Nine women had lowered values for both hormones, while in two 
levels were in the normal range. In the remaining 18 men the 
situation was strikingly different: 2 had high levels of LH and 
FSH, 14 were within the normal range, while only 2 had lowered 
values. However, 9 men had low testosterone levels. 
DISCUSSION 
Deteriorating vision is the most frequent initial complaint 
in patients with a nonfunctioning adenoma of the pituitary. 
However, especially in men impotence or loss of libido are 
noticed quite often, though in many of these patients it takes 
a long time before the diagnosis of a pituitary adenoma is 
established. The reason for this delay may be that patients do 
not seek medical attention for this type of complaint or that 
the physician does not consider the possibility of a pituitary 
tumor. 
In 9 out of 11 women with a nonfunctioning adenoma we observed 
low immuno-active LH and FSH levels, while in 16 out of 18 men 
immuno-active gonadotropin levels were normal or high. However, 
in 8 men a discrepancy between LH and testosterone levels 
existed. Since gonadotropin levels were assessed using immune-
assays with high crossreactivity of a-subunit and LHB, seemingly 
normal LH levels in men with low testosterone may have been 
caused by crossreactivity of circulating subunits. 
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4. CONFOUNDING FACTORS IN THE INTERPRETATION OF GONADOTROPIN AND 
GONADOTROPIN-SUBUNIT RELEASE FROM CULTURED HUMAN PITUITARY 
ADENOMAS. 
D.J. Kwekkeboom, F.H. DeJong and S.W.J. Lamberts. 
Department of Medicine , University Hospital Dijkzigt, 
Rotterdam, The Netherlands. 
Journal of Steroid Biochemistry, in press. 
ABSTRACT 
Culture data of 31 human pituitary nonfunctioning adenomas 
and effects of crossreactivity and in vitro culturing conditions 
on immunoreactivity of gonadotropins and subunits were inves-
tigated. 
Using immunoradiometric assays for FSH and LH and radio-
immunoassays for a-subunit and LHB-subunit cross-reactivities 
were reduced to a minimum. 
Repeated freezing and thawing had no effect on immuno-
reactivity of hormones and subunits tested. 
Incubation at 37°C did not affect the immunoreactivity of 
purified subunit preparations and no recombination of a-subunit 
and LHB into intact LH could be demonstrated after coincubation 
of the subunits. FSH immunoreactivity in culture media from 3 
pituitary tumors was not affected by incubation at 37°C. LH from 
a purified preparation and LH in culture media from 3 pituitary 
adenomas showed a rapid decrease of LH immunoreactivity when left 
at 37°C. 
Concomitant with decreasing LH levels at 37°C, a rise in the 
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concentration of a-subunit occurred. A direct correlation between 
gain in a-subunit and loss of LH was found. LHP levels remained 
stable while LH decreased. This observation may be attributed to 
an increase in LHP levels which is compensated by the loss of LH, 
which has a relatively high crossreactivity in the LHfi immuno-
assay. 
LH, FSH, a-subunit, LHB or a combination of these glycopro-
teins could be demonstrated in 26 out of 31 cultured tumors from 
patients operated upon because of a clinically nonfunctioning 
adenoma. In none of the media of 15 adenomas in which both a-
subunit and LH were detected, could a-subunit levels have been 
caused by dissociation of LH at 37°C. In two cases, measured LH 
levels could have been caused by crossreactivity of a-subunit and 
FSH. 
It was concluded that: 1. in research of nonfunctioning 
pituitary adenomas data on gonadotropin and gonadotropin-subunit 
secretion may suffer from bias caused by crossreactivity; 2. that 
dissociation of LH into subunits at 37°C is relatively unimpor-
tant in in vitro research of nonfunctioning adenomas; 3. that 
virtually all nonfunctioning pituitary adenomas contain or 
release gonadotropins and/or subunits. 
INTRODUCTION 
Secretion of LH, FSH, and the subunits of these hormones, a-
subunit, LHB and FSHB by human "nonfunctioning" pituitary 
adenomas has been reported by several authors over the past few 
years (1-23, for reviews see 11,16). In vivo hypersecretion of 
gonadotropins or a-subunit can be estimated to be relatively rare 
(4-17 % in larger series) (8,11,16,21). However, many, if not 
virtually,all nonfunctioning adenomas can be shown to produce 
gonadotropins or gonadotropin subunits in vitro (15,16,20,23-
26). 
Several causes might contribute to this discrepancy between 
in vivo and in vitro data: 
1. The majority of nonfunctioning adenomas appear to secrete 
gonadotropins and/or their subunits at a low rate: levels of 
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their secretory products in vivo may therefore well fall into the 
normal or even low range, while in vitro secretion of these 
products can be easily detected. 
2. A relatively high secretion of LH, FSH or one of the 
gonadotropin-subunits in vitro may cause appreciable immunore-
active levels of one of the other hormones because of mutual 
crossreactivity. 
3. The in vitro cell culture model may have features that are 
lacking under in vivo conditions. 
The aim of the present study was to investigate the effects 
of crossreactivity and in vitro culturing conditions on im-
munoreactivity of gonadotropins and gonadotropin-subunits in an 
attempt to evaluate in vivo and in vitro data in this type of 
tumors in a more satisfying way. 
MATERIALS AND METHODS 
In vitro investigations 
In vitro cell culture data were obtained as described before 
(27). In short, surgically removed tissue of nonfunctioning 
pituitary adenomas was washed several times, incubated with 
dispase, and transformed into a cell suspension using a Dounce-
type homogenizer. Centrifugation in a discontinuous Ficoll-
Isopaque gradient was applied to separate pituitary cells from 
blood elements. Finally, cells were suspended in Eagle's Minimum 
Essential Medium (MEM), containing 10% fetal calf serum (FCS). 
Thereafter, cells were cultured at 37°C in Costar multiwell 
plates, usually at a concentration of 200.000 cells per well. 
Incubations, with or without addition of drugs or hormones were 
performed in fourfold and generally lasted for 24 to 92 hours. 
To evaluate the effect of exposure of LH, FSH, a-subunit and 
LHB-subunit to the conditions of cell culture and immunoassay, 
we investigated the changes of immunoreactive gonadotropin and 
subunit levels after incubation at elevated temperature. Two 
different purified LH and FSH preparations, purified a-subunit 
and LHB preparations and a combination of these two subunit 
preparations, were diluted in MEM containing 10% FCS. Of each 
36 
preparation, two separate dilutions were left at 37°C and at 20°C 
for o, 4, 24, and 48 hours respectively. Each incubation was 
performed in triplicate. Preparations used were for LH: MRC 68/40 
and a preparation from KABI, Stockholm, Sweden; for FSH: a 
preparation from IRE-Medgenix, Brussels, Belgium, and a prepara-
tion from KABI; for a-subunit MRC 78/554, and for LHB-subunit 
MRC 78/556. Culture media of three pituitary adenomas that 
contained LH, FSH, a-subunit and LHB-subunit were also incubated 
at 37°C for 0, 4, 24 and 48 hours. 
To evaluate the effect of repeated freezing and thawing, a 
procedure frequently used to lyse cells after culture in order 
to be able to estimate hormone contents of cells, on LH, FSH and 
gonadotropin-subunit levels 10 patient sera were frozen and 
thawed 1 to 5 times, followed by estimation of horm~ne levels. 
The relation between testosterone (T) and LH values was 
evaluated in 14 men with a nonfunctioning pituitary adenoma. A 
comparison was made between LH levels as measured u~ing double 
antibody immunoassays (antibodies from KABI and UCB) and LH 
levels as measured using the radioimmunometric assay mentioned 
below. 
Immunoassays 
Immunoassays applied were: for LH and FSH immunoradiometric 
assays (IRMAs) supplied by IRE-Medgenix, Brussels, Belgium. 
Incubation time of these assays was 2 hours. Intra- and inter-
assay coefficients of variation (CVs) of these assays were for 
LH <5% and <15%, for FSH <3% and <8%, respectively. Sensitivi-
ties (as defined by two standard deviations of the blank) were 
for the LH IRMA 0.05 ngjml (0.3 miUjml) and for the FSH IRMA 
0.03 ngjml (0.3 miUjml). 
For the estimation of a-subunit and LHB double antibody RIAs 
were applied using antibodies purchased from UCB, Brussels, 
Belgium. Incubation in these assays was overnight. Intra- and 
interassay cvs of these assays were: for a-subunit <6% and <11%, 
for LHB <7% and <13%, respectively. Sensitivities (as defined by 
a 10 % decrease of the initial binding) were for the a-subunit 
assay 0.2 ngjml and for the LHB assay 0.5 ngjml. Standards used 
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were for IJI: MRC 68/40 (potency: 6.6 miUjng), for FSH: a 
preparation from KABI, Stockholm, sweden (potency: 8.7 miUjng), 
for a-subunit: MRC 78/554 (potency: 1 miUjng) and for IJIB: MRC 
78/556 (potency: 1 miUjng). 
Crossreactivities in the immunoassays were determined using 
the above mentioned standard preparations. 
statistics 
For comparison of slopes of regression lines Student's t-test 
was used. Other tests used are mentioned in the text. 
RESULTS 
Crossreactivities of gonadotropins and subunits in the various 
irnrnunoassays have been summarized in Table 1. 
Table 1. Crossactivity of hormones and subunits in immunoassays 
Assays LH assay FSH assay a·subunit LH{J assay 
assay 
Hormone 
LH 100 0.06 (0.08) 3.9 (0.6) 53.4 (8.1) 
FSH 0.5 (0.4) 100 20.0 (2.3) 1.1 (0.1) 
a-subunit 0.4 (2.7) 0.06 (0.5) 100 1.8 (1.8) 
LH{J-subunit < 0.5 (<3.2) <0.01 (<0.1) 0.2 (0.2) 100 
Crossreactivity of hormones and subunits in gonadotropin- and subunit 
immunoassays, in ng/ng and, between brackets, in miU/miU; values are 
percentages. 
The effect of repeated freezing and thawing on immuno-
reactivity of LH, FSH, a-subunit and LHB is summarized in Table 
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2. Applying Spearman's Rank correlation Test on individual serum 
levels, no significant changes of hormone concentrations could 
be shown. 
Table 2. Effects of repeated freezing and thawing on glyco-
protein hormone immunoreactivity in patient serum samples. 
Individual serum sample levels after thawing once have been 
taken as 100%. Values listed are mean percentages, and, 
between brackets, standard deviations, of 10 samples. 
Frequency of thawing 
1x 2x 3x 4X sx 
Hormone levels 
LH 100 98 (3 .1) 99 (6.3) 95 (6. 6) 96 (5.5) 
FSH 100 103 (5. 0) 104 (2.5) 101 (6.6) 103 (3. 6) 
a-subunit 100 100 (7. 4) 98 (11.1) 98 ( 11.3) 105 (11. 7) 
LH.B 100 104 (7. 6) 100 (8 .1) 100 (9. 9) 103(13.8) 
The relation between peripheral levels of testosterone and 
LH in 14 men with a nonfunctioning pituitary adenoma is sum-
marized in Table 3. In 3 of these 14 men a-subunit levels and 
in one LHB levels were elevated. Using a radioimmunoassay with 
polyclonal antibodies, a discrepancy between LH and T levels was 
observed in 8 men. Using the immunoradiometric assay, a dis-
crepancy between LH and T levels was noticed in only 3 patients. 
None of these three had elevated subunit levels. 
Table 3. LH and Testosterone levels in 14 men with a pituitary 
nonfunctioning adenoma. Levels are stated in reference to 
normal values for the immunoassay. 
LH by RIA LH by IRMA Total 
high normal low high normal low 
Testosterone 
normal 2 4 6 6 
low 6 2 3 5 8 
In figure 1 the effect of prolonged exposure to 37°C on LH 
immunoreactivity of two LH preparations is depicted. The MRC 
reference preparation 68/40 showed a significantly slower decay 
of LH immunoreactivity than the KABI preparation (P<0.05). 
Regression lines of LH decay in culture media of three non-
functioning pituitary adenomas were parallel to that of the KABI 
preparation, but differed significantly from that of MRC 68/40. 
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Figure 1. Effect of prolonged exposure to· 37°C on LH im-
munoreactivity. Regression lines and (shaded area) 95% con-
fidence limits for the prediction of individual values. I : 
KABI preparation; II: MRC 68/40; e A • : LH in media of 
cultured cells from pituitary adenomas. 
At a temperature of 20°C LH immunoreactivity showed a 
significant, though slow decrease (data not shown). The slope 
of the regression line at 20°C was significantly lower than that 
of the same preparation at 37°C (O.OOOSJh. versus 0.006). 
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Figure 2. Effect of prolonged exposure to 37°C on FSH 
immunoreactivity. Regression line and (shaded area) 95% 
confidence limits for the prediction of individual values. 
• "" • : FSH in media of cultured cells from pituitary 
adenomas. 
In figure 2 the effect of exposure to 37°C on FSH immuno-
reactivity in the KABI and Medgenix preparations is shown. As the 
slopes of the lines for the two tested preparations did not 
differ significantly, data were combined. Data on FSH decay in 
individual tumorous cell cultures did not show a significant 
regression, however. Exposure to 20°C did not have any effect on 
FSH levels of purified preparations (data not shown). 
Exposure to a temperature of 37°C of a-subunit and LH.B-subunit 
did not affect immunoreactivity of the subunits (data not shown). 
Neither did we notice any effect on a-subunit or LH.B immunoreac-
tivity when these purified preparations were combined and left 
at 37°C for 48 hours. Moreover, no change in LH immunoreactivity 
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of the combined a-subunit and LHB preparation was observed after 
48 hours of exposure to 37°C. 
A rise in a-subunit levels concomitant with the decrease in 
LH levels in LH preparations was noticed, after incubation at 
20°C and 37°C. The gain in a-subunit levels was directly corre-
lated to the loss of LH immunoreactivity, irrespective of tem-
perature or preparation tested. This relationship is depicted in 
fig 3. The gain in a-subunit (ng) could be estimated to be 41 ± 
4% (slope (b) ± standard error of the slope (sb)) of the loss 
in LH immunoreactivity, expressed in ng of the MRC 68/40 stan-
dard. Data on the relationship between loss of immunoreactive LH 
and gain of a-subunit in pituitary cell culture media were in 
concordance with this regression line. 
1 3 
gain in a-subunit 
reactivity ( ng /ml) 
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Figure 3. Gain in a-subunit immunoreactivity (ngjml) versus 
loss of LH immunoreactivity (ng/ml) in LH preparations. 
Regression line and (shaded area) 95% confidence limits for 
the prediction of individual values. 
No significant difference in LHB immunoreactivity in the LH 
preparations tested could be shown, neither after exposure to 
37°C nor to 20°C. 
Culture data of pituitary tumor cells from 31 patients who 
were operated upon because of a clinically nonfunctioning adenoma 
and in whom the existence of a pituitary tumor was confirmed by 
histologic examination of the removed tissue, are listed in Table 
4. In media in which FSH was demonstrated, values per 24 hours 
of culturing and 106 cells ranged from 0.2 to 367.8 ngjml; for a-
subunit values ranged from 0.3 to 320.0 ngjml, for LHB from 2.4 
to 82.1 ngjml and for LH from 0.4 to 6.7 ngjml. In two culture 
media, measured LH and LH and LHB levels, respectively, could 
have been caused by crossreactivity of a-subunit and FSH. In none 
of the media in which a-subunit was detected could levels of this 
subunit have been caused by dissociation of LH at 37°C. 
Table 4. Frequency distribution of hormones and subunits in 
cell cultures of 31 nonfunctioning pituitary adenomas. 
Hormones and Total 
subunits detected 
LH, FSH, LH/3, a-subunit 10 3 13 
a-subunit 1 3 4 
LH/3 2 1 3 
FSH 1 0 1 
FSH, a-subunit 1 1 2 
FSH,LH/3 0 1 1 
LH, LH{3,a·subunit 2 0 2 
ACTH 1 2. 3 
None 0 2 2 
Total 18 13 31 
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DISCUSSION 
Several authors have reported secretion of gonadotropins and 
their subunits by pituitary nonfunctioning adenomas in vivo and 
in vitro (for reviews see 11,16). However, the results presented 
were often obtained using radioimmunoassays in which separate 
subunits or intact hormones show considerable mutual crossreac-
tivity. The immunoassays for FSH, LH and a-subunit used in this 
study, show low crossreactivity for the other gonadotropins or 
subunits. An example of the importance of low crossreactivity in 
immunoassays is given in Table 3: LH levels as measured using 
radioimmunoassays showed a discrepancy with testosterone levels 
in 8 out of 14 patients with a pituitary nonfunctioning adenoma. 
Using the immunoradiometric assay, a discrepancy between LH and 
T levels was noticed in only 3 patients. In these patients 
hypogonadism or circulating biologically inactive forms of LH may 
have been present. 
Other factors which might confound the interpretation of data 
are the influence of repeated freezing and thawing of samples and 
the spontaneous dissociation of gonadotropins or the reasso-
ciation of gonadotropin-subunits during culture. 
The results obtained after repeated freezing and thawing show 
that there are no significant changes in the levels of im-
munoreactive LH, FSH, a-subunit or LHB. This is in concordance 
with the findings of other investigators {28). 
Loeber et al. {29), reported that LH in solution dissociates 
at elevated temperatures into subunits, regardless of the 
presence or absence of enzyme inhibitors. Similar studies have 
not been reported for gonadotropins in the medium of cultured 
gonadotropin producing pituitary tumors. After incubation of two 
different purified LH preparations for various periods at 37°C 
and at 20°C a clear decay of LH levels was found, accompanied by 
a rise in a-subunit levels, while LHB immunoreactivity did not 
change. Significantly different slopes for the decay of LH 
preparations at 37°C were obtained. This difference might be due 
to a different method of purification of the preparations or to 
a difference in constituting LH components {30). Cell culture 
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media of gonadotropin producing pituitary adenomas showed 
decreases of immunoassayable LH levels that were comparable with 
the decay of the KABI LH preparation. 
After log transformation of the data, straight regression 
lines of time of exposure versus LH levels as a percentage of 
the level before exposure to 37°C could be obtained. This means 
that a constant percentage of the LH available dissociated. 
Assuming a constant secretion rate of LH by LH producing 
pituitary tumors, and therefore an average exposure time of LH 
to 37°C of 24 hours in cell cultures lasting 48 hours, this means 
that 28% of the LH released may dissociate. 
The loss of initially present immunoreactive LH after exposure 
to 20°C or 37°C was directly correlated to an increase in a-
subunit levels. In cell cultures of gonadotropin secreting 
pituitary adenomas, in which both LH and a-subunit are found, a-
subunit levels will have to exceed not only the amount of 
immunoreactivity which may be due to crossreactivity of LH 
present, but also the amount due to dissociation of LH initially 
present, to prove that a-subunit secretion by the adenomatous 
cells actually took place. In none of the 15 cultures of 
pituitary adenomas listed in Table 4 in which both a-subunit and 
LH were detected, could a-subunit levels have been caused by 
dissociation of secreted LH. This is due to the fact that amounts 
of LH released by these nonfunctioning adenomas in vitro are low 
in comparison with released amounts of subunits. 
Dissociation of LH at 20°C was noticed. As the LH IRMA only 
takes 2 hours of incubation, and the slope of the decay line at 
20°C is rather flat, an accurate estimation of the LH level can 
be obtained. In the a-subunit assay, however, samples are 
incubated for 24 hours. In these samples, 2.2 % of the initial 
LH, if present, will have dissociated, giving rise to 0.41 x 2.2% 
= 0.9% a-subunit immunoreactivity in relation to LH levels. This 
is far less than LH crossreactivity in the a-subunit assay (being 
3.9%), but presumably forms a part of it. 
Rising a-subunit levels accompanying decreasing LH levels at 
37°C and 20°C suggest the dissociation of LH into a-subunit and 
LHB-subunit. However, we did not find a significant trend 
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indicating an increase in LHB concomitant to LH decrease. This 
observation can be explained by a rise in "true" LHB levels that 
is about equal to the decrease of LH crossreacting in the LHB 
assay. So, we assume that the gain in LHB accompanying LH 
dissociation is about equal to the the crossreaction of LH in 
the LHB assay, i.e. 53% (ngjng). In the evaluation of LHB 
concentrations, this means that LHB immunoreactivity has to 
exceed 53% of the LH levels to allow any conclusion as to what 
hormone is actually being measured. 
A decrease in FSH immunoreactivity of purified FSH prepara-
tions during exposure to 37°C was found. In comparison to LH, 
however, the rate of FSH decay was low. FSH produced by gona-
dotropin secreting pituitary tumours did not show a significant 
trend of decay at all, just. as purified FSH at 20°C could not be 
shown to decrease in immunoreactivity. Therefore, dissociation 
of FSH under in vitro conditions is not likely to affect the 
interpretation of the results. 
Apart from dissociation of LH at various temperatures, we 
also investigated the possibility of association of subunits 
into LH at 37°C as reported by various authors (31,32). We did 
not find decreasing subunit levels or increasing LH levels. The 
reason for this may be that we studied combinations of subunits 
in relatively low concentrations (up to 100 ngjml), while it has 
been pointed out (33) that high concentrations (>1 mgjml) are 
needed to favour association. 
Summarizing, it is concluded that: 1. in research of non-
functioning pituitary adenomas data on gonadotropin and gona-
dotropin-subunit secretion may suffer from bias caused by 
crossreactivity of these hormones and subunits in their res-
pective immunoassays; 2. that dissociation of LH into subunits 
at 37°C occurs, but is relatively unimportant in in vitro 
research of pituitary nonfunctioning adenomas, because amounts 
of LH released by this type of tumor are low in comparison with 
released amounts of a-subunit; 3. that virtually all human 
pituitary nonfunctioning adenomas contain or release gonadotro-
pins andjor their subunits. 
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ABSTRACT 
We studied the in vivo hormonal levels and in vitro hormone 
and subunit release in a group of 22 patients who were operated 
upon because of a clinically nonfunctioning or gonadotroph 
pituitary adenoma. In vivo, 5 of the 22 patients, all of whom 
were men, had hypersecretion of FSH, LHB or a-subunit. An 
elevated ratio of serum a-subunit to LH and FSH was found in 6 
of 8 women in vivo, although in all 6 women serum LH, FSH and 
a-subunit levels were low. LH, FSH, a-subunit, LHB or a com-
bination of these glycoprotein hormones could be demonstrated 
in 19 of 22 cultured adenomas. 
We conclude that: 1. virtually all clinically nonfunctioning 
adenomas contain or release gonadotropins or their subunits in 
vitro; 2. in vivo hypersecretion of these hormones and subunits 
occurs infrequently and in this series only in men; 3. an 
elevated ratio of a-subunit to LH and FSH is frequently found in 
women and may prove a useful diagnostic tool; 4. responses to TRH 
and bromocriptine do not depend on baseline gonadotropin levels, 
neither in vivo nor in vitro, implying that the distinction 
between gonadotroph adenomas and adenomas without hypersecretion 
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of gonadotropins in vivo is absent where hormone dynamics are 
concerned. 
INTRODUCTION 
Production, both in vivo and in vitro, of LH, FSH and their 
subunits, a-subunit, LHB and FSHB by human pituitary adenomas 
has been reported by several authors (1-30, for reviews see 
11,16). Based on the presence or absence of elevated serum 
gonadotropin or subunit concentrations, it is possible to 
distinguish between gonadotroph and clinically nonfunctioning 
pituitary adenomas. In most of the clinically nonfunctioning 
adenomas, immunostaining for the anterior pituitary hormones is 
negative (21), but some may immunostain for gonadotropins or 
subunits (23). Moreover, many clinically nonfunctioning adenomas 
produce gonadotropins or gonadotropin subunits in vitro (15,16, 
20,23-26). Therefore, it may be questioned whether gonadotroph 
and clinically nonfunctioning tumors represent two different 
entities. Most reports on in vivo and in vitro gonadotropin 
production by clinically nonfunctioning adenomas and gonadotroph 
adenomas deal with small groups of patients, making general 
conclusions difficult. We investigated the in vivo hormonal 
levels, and the in vitro hormone- and subunit release in a group 
of 22 patients who were operated upon because of a clinically 
nonfunctioning or gonadotroph pituitary adenoma, and evaluated 
the influence of several parameters on hormone and subunit 
release in vivo and in vitro. 
PATIENTS AND METHODS 
Patients 
We studied 22 patients who were treated by trans~phenoidal 
surgery because of a clinically nonfunctioning or gonadotroph 
pituitary adenoma between 1980 and 1987. Serum gonadotropin and 
subunit concentrations had been measured in all patients, and in 
each the presence of a pituitary tumor was verified by histologic 
examination of the removed tissue. The protocol was approved by 
the hospital's ethical committee and each patient gave informed 
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consent for the studies. 
In vivo investigations 
The responses to 200 ~g TRH and 100 ~g GnRH were studied on 
separate days. Blood samples were collected before and 10, 20, 
30, 60 and 120 minutes after iv TRH or GnRH injection. Bromo-
criptine (2.5 mg) or a placebo was given orally and blood samples 
were collected hourly for 12 hours on other days. 
In vitro investigations 
In vitro cell culture data were obtained as described 
previously (31). Surgically removed pituitary tumor tissue was 
washed several times, incubated with dispase, and the cells 
dispersed using a Dounce type homogenizer. The tumor cells were 
seperated from blood cells by discontinuous Ficoll-Isopaque 
gradient centrifugation, and then were suspended in Eagle's 
Minimum Essential Medium (MEM) containing 100 gjL fetal calf 
serum (FCS) and cultured at 37°C in Costar multiwell plates, 
generally at a concentration of 200.000 cells per well. After 
renewal of the media on day 4, the cells were incubated with or 
without TRH (100 nmoljL; Hoechst, Frankfurt am Main, FRG), GnRH 
(100 nmoljL; Hoechst) or bromocriptine (10 nmoljL; Sandoz, Basel, 
Switzerland) in quadruplicate for 24 to 72 hours. Thereafter, the 
media were stored at -20°C for hormone assay. In most cultures, 
cells obtained both before and after these incubations were lysed 
in distilled water containing 1 gjL bovine serum albumin by 
repeated freezing and thawing and the hormone concentrations in 
these lysates were measured. 
Immunoassays 
Prolactin, GH and ACTH were measured using radioimmunoassay 
(RIA) kits obtained, respectively, from IRE-Medgenix, Brussels, 
Belgium, Sorin, Milano, Italy, and The Radiochemical Center, 
Amersham, UK (20,31). TSH was measured using a kit obtained from 
Behring, Marburg, FRG. The sensitivity of the assay was 0.1 mU/L 
and the crossreactivities of subunits and gonadotropins were <1% 
and <0.01%, respectively. 
52 
FSH and LH were measured using immunoradiometric assay kits 
supplied by IRE-Medgenix, Brussels, Belgium. The sensitivity of 
these assays was 0.5 IU/L. a-subunit and LHB were measured by RIA 
using antibodies purchased from UCB, Brussels, Belgium. The 
sensitivity of the a-subunit assay was 0.3 ~g/L and that of the 
LHB assay was 1.0 ~gjL. LH was expressed in terms of the MRC 
68/40 reference preparation, FSH in terms of the MRC 78/549 
reference preparation, and a-subunit and LHB in terms of MRC 
78/554 and 78/556, respectively. 
The crossreactivities on a weight/weight basis were: LH assay 
-FSH 0.5%, a-subunit 0.4%, LHB <0.5%; FSH assay -LH and a-subunit 
0.06 %, LHB <0.01%; a-subunit assay -LH 3.9%, FSH 20.0%, LHB 
0.2%; LHB assay -LH 53.4%, FSH 1.1%, and a-subunit 1.8%. The 
intra- and interassay coefficients of variation of the assays 
were, respectively, <5% and <15% for LH, <3% and <8% for FSH, <6% 
and <11% for a-subunit, and <7% and <13% for LHB. 
Statistics 
In vitro hormone release was evaluated using one way analysis 
of variance (ANOVA) . Log transformation of data was used to 
stabilise variance. For the comparison of treatment means the 
Newman Keuls method was applied (32). P values <0.05 were 
considered significant. 
RESULTS 
In vivo investigations 
The mean age of the 14 men was 54.3 ± 11.7 (SD) years (range 
32-69) and that of the 8 women was 60.6 ± 10.3 (range 40-71) 
(P>0.05 by Student's t test). Eighteen patients (10 men and 8 
women) had visual symptoms, 9 men had impotence and decreased 
libido, 1 woman had decreased libido, and 5 men and 2 women had 
headaches or drowsiness. 
Signs of hypopituitarism, manifested by low serum T4 levels 
andjor a decreased response to metyrapone, were present in 5 of 
21 (24%) and 13 of 16 (81%) patients, respectively, and 1 patient 
who had autoimmune thyroiditis had an elevated serum TSH and a 
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low T4 level. Thirteen patients had slightly elevated serum 
prolactin values (range: 12.3-38.1 ~g/L; normal values: <12 ~g/L 
in men and <15 ~g/L in women). No patient had an elevated plasma 
GH or ACTH concentration. The presence or absence of abnormal 
levels of the above mentioned hormones did not differ sig-
nificantly between sexes (P>O.OS by Fisher exact tests). Serum 
testosterone levels were low in 8 men. 
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Table 1. Serum gonadotropin and subunit concentrations in 22 
patients with a clinically non functioning or gonadotroph 
pituitary adenoma. Concentrations are means of 2 or more 
values. 
Serum 
LH FSH <X-subunit LH~ <X-subun~/ cell-culture 
(lUll) (lUll) fl91l fl91l gonadotropin number 
ratio(%) 
Men 3.1 24.1" 1.2" < 1.0 4.4 
3.4 46.2" 2.7" <1.0 5.4 2 
2.2 12.8" 0.7 < 1.0 4.7 1 
2.7 4.9 0.8 <1.0 10.5 
2.5 4.6 0.6 <1.0 8.5 
2.8 3.9 0.9 < 1.0 13.4 5 
5.5 4.7 1.0 <1.0 9.8 
3.2 3.9 0.8 <1.0 11.3 
1.6" 4.0 0.9 <1.0 16.1" 4 
1.o· 2.5 2.6" < 1.0 74.3" 8 
1.0" 4.4 0.6 1.1" 11.1 10 
1.5" 3.2 0.3" <1.0 6.4 
1.8" 4.2 <0.3" < 1.0 <5.0 6 
2.1 3.8 0.5 <1.0 8.5 a 
Women 
premenopausal 3.6 12.5 0.5 <1.0 3.1 a 
menopausal 
6.3" 14.3" 0.5" <1.0" 2.4 7 
1.6" 4.6" 0.7" <1.0" 11.3" 
0.9" 6.2" o.6· <1.0" 8.5· 
1.2" 8.2" 0.7" <1.0" 7.5" 3 
<0.5" 4.0" 0.8" <1.0" > 17.8" 
<0.5" 4.9" o.6" <1.0" >11.1" 
o.6· 1.8" o.s· <1.0" 33.3" 9 
Normal values 
Men 1.9-9.2 1.6-11.1 0.4-1.1 <1.0 3.8-16.0 
premenopausal women 1.1-49.5 1.8-46.0 0.3-2.3 < 1.Q-3.8 2.4-16.7 
menopausal women 17.5-86.6 26.2·107.7 1.3-4.0 1.4·5.4 1.4·3.3 
•: abnormal concentration. The numbers in the cell culture 
column correspond to the patient numbers in Figure 1 and Table 
3. a: Cell culture in which ACTH was detected. 
The serum gonadotropin and subunit levels in the individual 
patients are shown in Table 1. The a-subunit/gonadotropin ratio 
listed in the table was computed by dividing the a-subunit level 
by the sum of the LH and FSH levels and multiplying the result 
by 100. Three of the 22 patients {14%), all of whom were men, had 
gonadotroph adenomas, defined by supranormal serum LH or FSH 
concentrations. In comparison to normal values, 6 of the 14 men 
had elevated serum FSH, a-subunit, LHB or an increased a-
subunit/gonadotropin ratio. Low serum gonadotropin and a-subunit 
levels were found in 7 of the 8 women, and the a-subunit/gonado-
tropin ratio was high in 6 women. Compared to their respective 
normal values, low serum LH, FSH, and a-subunit levels and an 
increased a-subunit/gonadotropin ratio were found significantly 
more frequently in women than in men (chi-square tests; P<0.01 
in all instances). 
The mean absolute serum LH, FSH, and a-subunit levels and the 
a-subunit/gonadotropin ratio were similar in the men and women. 
Light microscopy revealed a basophilic adenoma in one patient, 
and a chromophobe adenoma in 21 patients. 
In vitro investigations 
No hormones were detected in 1 patient's cells or media, while 
LH, FSH, a-subunit, LHB or a combination were found in the media 
andjor cells from 19 tumors (Table 2). TSH was found in one 
culture. No GH or prolactin was·found in any culture. ACTH alone 
was found in 2 tumors, although neither patient had any bioche-
mical findings of cushing's disease; the tumor tissue of one of 
these patients was basophilic. 
The absence or presence of LH, FSH, a-subunit and LHB did not 
differ significantly between men and women (P>0.05; Fisher exact 
tests), nor was there a significant difference in the simul-
taneous presence of all four measured gonadotropins and subunits 
between the sexes. 
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Table 2. Frequency distribution of hormones and subunits in 
media andjor cells of clinically nonfunctioning pituitary 
adenomas or gonadotroph pituitary adenomas from 22 patients. 
Hormones and Total 
subunits detected 
LH, FSH, LH~,~-subunit 7 1 8 
~-subunit 1 2 3 
LH~ 2 0 2 
FSH 1 0 1 
FSH, ~-subunit 1 1 2 
FSH, LH~ 0 1 1 
LH, LH~.~-subunit 1 0 1 
LH, FSH, LH~.~-subunit, TSH 0 1 1 
ACTH 1 1 2 
None 0 1 1 
Total 14 8 22 
The presence of gonadotropins and subunits in culture media 
could be evaluated in 20 of the 22 tumors, since in 2 tumors 
only cell hormone analyses were' done. A discrepancy between media 
and cell gonadotropin and subunit content was found in the 
cultures of 6 patients: LH, LHB or FSH were present in the cells, 
but were not detected in the culture media from 2, 3 and 3 
tumors, respectively. In the media of 2 tumors.the measured LH 
or LH and LHB levels, respectively, could have been caused by 
crossreactivity of a-subunit or FSH. 
The frequency of release of LH, FSH, a-subunit and LHB did 
not differ significantly between sexes, although the LH release 
was detected in 6 of 12 cultures from men, and in only 1 of 8 
cultures from women. The release of LH, FSH, LHB and a-subunit 
per 24 hours and 106 cells did not differ significantly between 
sexes (P>0.05 ; Mann-Whitney U-tests). 
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In media in which FSH was detected, the values per 24 hours 
and 106 cells ranged from 1.3 to 3200.0 IU/L, for a-subunit from 
0.3 to 320.0 ~gjL, for LH from 2.7 to 29.5 IU/L and for LHB from 
2.4 to 82.1 ~gjL. 
Comparison of in vitro and in vivo hormone levels 
In 20 patients in whom in vitro release of hormones was 
measured, the amounts of LH and FSH released in vitro per 106 
cells and 24 hours and the serum hormone values were not 
correlated. For a-subunit, however, a significant correlation 
was found (Spearman Rank correlation test ; r 5=0.574, P<0.01). 
As LHB was detected in vivo in only one patient, no correlation 
test was performed. 
In vivo effects of TRH. GnRH and bromocriptine 
In 6 patients the effects of placebo administration were 
studied for 12 hours. Their serum LH, FSH and a-subunit levels 
varied by up to 38%, 32% and 25% of the respective baseline 
levels. Therefore, responses over 40% of the baseline level for 
LH, over 35% of the baseline level for FSH and over 30% of the 
baseline level for a-subunit were considered significant. 
The response to TRH was evaluated in is patients (11 men and 
7 women). A significant increment of LH, FSH and a-subunit 
occurred in 1, of LH and a-subunit in 3, of FSH and a-subunit 
in 2, of FSH only in 1 , of LH only in 2, and of a-subunit only 
in 4. Thus, 13 of 18 patients (72%) had a rise in serum gonado-
tropin or a-subunit levels. The percentage increase was indepen-
dent of the baseline hormone levels (Spearman Rank correlation 
tests), and was not related to sex (Mann-Whitney U-tests). The 
number of significant responses also did not differ significantly 
between men and women (chi-square tests). 
Bromocriptine administration in 3 patients resulted in a 
significantly decreased serum a-subunit level in 1 patient. In 
2 of these 3 patients, a TRH test had been performed. Both had 
an increase in one or more glycoprotein hormone levels after TRH 
administration. 
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Fig. 1 Effects of TRH, GnRH and bromocriptine on mean (± SE) 
glycoprotein hormone release by 10 human nonfunctioning ade-
nomas in vitro. Release is shown per 106 cellsfmL and per 24 
hours. (In patient 3 LH values during incubation with bromo-
criptine were undetectable). D control; Ill TRH 100 nmolfL; • 
GnRH 100 nmolfL; IS bromocriptine 10 nmolfL. •: P<O.OS; ** 
P<O. o 1 by Newman Keuls method for comparison of means in 
ANOVA. 
GnRH tests were performed in 4 patients. Serum LH levels 
increased by 81 to 238% and a-subunit levels increased by 33 to 
125% in these 4 patients. Serum FSH levels increased by 39 to 
200% in 3 patients. 
In vitro effects of TRH, GnRH and bromocriptine 
The effects of bromocriptine (10 nmoljL), TRH (100 nmol/L) 
and GnRH (100 nmoljL) were studied in vitro in 8, 7 and 10 
tumors, respectively. Bromocriptine inhibited hormone release 
significantly in 5 of the 8 tumors. TRH and GnRH significantly 
stimulated hormone release in 4 of 7 and 4 of 10 tumors, 
respectively (Fig. 1). The number of cultures in which sig-
nificant responses to one or more agents were found did not 
differ significantly between those cultured for 24 hours and 
those cultured longer (1 of 4 and 4 of 6 cultures, respectively; 
P=0.26, Fisher exact test). 
No relationship between the type of hormones or subunits 
released and susceptibility to suppression or stimulation was 
found (Fisher exact tests; P>0.05). Neither was there a rela-
tionship between the amount of glycoprotein hormones released 
and the effectiveness of GnRH, bromocriptine and TRH (Mann-
Whitney U-tests; P>0.05). 
In the 7 cultures in which bromocriptine, GnRH and TRH were 
tested, the release of one or more gonadotropins and subunits 
changed significantly in response to all three substances in 4, 
while 3 responded to none. (P<O. 05; Fisher exact test). 
Comparison of in vitro and in vivo responses to TRH. GnRH, and 
bromocriptine 
In 8 patients the in vivo responses to TRH, GnRH or bromocrip-
tine (Table 3) could be compared with in vitro results (Fig 1). 
Nine of the 10 significant changes of serum LH, FSH,and a-subunit 
concentrations in response to TRH, GnRH and bromocriptine 
administration in vivo were mimicked in vitro. Serum gonadotropin 
and a-subunit concentrations did not change significantly after 
TRH, GnRH or bromocriptine administration on 15 occasions in 
vivo, but in vitro the levels of the corresponding hormone or 
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subunit responded to these substances with a significant change 
on 8 occasions. In the 8 patients 10 in vivo tests were per-
formed. The tumors of these 8 patients responded in vitro to 7 
tests with a significant change of the UI, FSH or a-subunit 
concentrati~n; this response was mimicked for at least one 
hormone in vivo in 6 tests. In the remaining 3 tests, no 
significant changes occurred in any hormone, either in vivo or 
in vitro (P<0.05 ; Fisher exact test). 
Table 3. Effects of TRH (200 ~g), GnRH (100 ~g) and bromoc-
rigtine (2.5 mg} on hormone- and subunit levels in 8 patients 
TRHtest Bromocriptine test 
lH FSH oc-subunit lH FSH oc-subunit 
Patient (lUll) (IU/L) (f.19/l) (lUll) (lUll) (119/l) 
1 
2 
3 
4 
5 
6 
8 
4 
9 
basal-max basal-max basal-max basal-min basal-min basal-min 
2.2-2.2 12.8-13.6 0.7-0.6 
3.4-5.5* 46.2-51.3 2.7-4.4* 
1.3-2.1* 9.7-12.0 0.7-0.8 1.2-1.2 8.2- 7.6 0.7-0.6 
1.6-2.1 4.G- 5.7* 0.9-1.2* 
1.8-1.7a 
2.8-1.8 3.~- 2.7 0.9-0.5* 
4.2- 4.5 <0.3-<0.3 
1.G-1.7*a 2.5- 3.1a 2.6-3.3 
GnRHtest 
1.6-5.4* 4.G- 8.4* 0.9-1.2* 
0.6-1.2*a 1.8- 5.4*a 0.8-1.2* 
Patient numbers refer to figure 1. •: significant response, 
as defined in the text. a: hormone not detected in vitro. 
DISCUSSION 
The absence of a specific clinical syndrome caused by 
overproduction of a hormone is characteristic, but not specific, 
60 
for patients who have a clinically nonfunctioning pituitary 
adenoma or a gonadotroph adenoma. Complaints caused by local 
tumor growth, i.e. visual complaints, drowsiness and headache, 
were predominant in this series, being present in 20 of the 22 
patients (91%). 
In vivo hypersecretion of FSH, a-subunit or LHB was found in 
5 of the 22 patients {23%). Other groups have reported elevated 
serum gonadotropin and subunit concentrations in 4-17% of such 
patients (8,11,16,21). This relatively low prevalence of 
gonadotroph adenomas in comparison to clinically nonfunctioning 
adenomas contrasts with the reports of in vitro release of 
gonadotropins and subunits by clinically nonfunctioning adenomas 
(15,16,20,23-26). It appears that most, if not all, such non-
functioning adenomas contain or release LH, FSH, a-subunit and 
LHB (23,25,26). Our finding that 19 of 22 ademonas contained or 
released gonadotropins andjor subunits in vitro provides further 
evidence that the term nonfunctioning might at best be limited 
to the clinical presentation. 
Two adenomas in this group contained or released ACTH in 
vitro, but neither patient had cushing's disease. In both 
patients the 0800 h. plasma cortisol concentrations were within 
the normal range and one patient had a normal decrease of plasma 
cortisol in response to 1 mg dexamethasone and a normal cortisol 
production rate. Therefore, these two tumors can be regarded as 
silent corticotroph adenomas (33,34). 
In one cultured adenoma no hormones or subunits could be 
demonstrated; it is unclear whether this tumor actually produced 
no glycoprotein hormones at all, or whether a substance not 
tested for, i.e. FSHB, was secreted. In the cultured tumor from 
one patient TSH was released in combination with LH, FSH, LHB and 
a-subunit, but the patient • s serum glycoprotein hormone and 
subunit concentrations were not elevated, and the serum T4 
concentration was normal (91 nmol/L). Asa et. al. (23) also have 
reported tumors that released all three glycoprotein hormones and 
a-subunit. They suggested that the tumor cells might derive from 
a precursor cell of the glycoprotein cell line. 
A significant correlation between hormone release per 24 hours 
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and per 106 cells in vitro and in vivo hormonal levels was found 
for a-subunit, but not for LH and FSH. These findings may be due 
to the fact that in 14 of the 20 cultures in which a correlation 
could be computed a-subunit was released, whereas LH and FSH 
were released in only 7 and 9 cultures. Moreover, the quantity 
of normal pituitary tissue which might be present in vivo and the 
tumor volume might bias the correlation between in vitro and in 
vivo data. 
In this series, all 5 patients with elevated serum gonado-
tropin andjor subunit concentrations were men. This observation 
correlates with the fact that the majority of pituitary adenomas 
with hypersecretion of gonadotropins or subunits so far described 
have been found in men (1-3 ,5, 6, 9,11-16,18-20,24,27,29, 30, 35, 36). 
However, most women who have a clinically nonfunctioning 
pituitary adenoma are menopausal, and the elevated serum 
gonadotropin and subunit values that occur normally in menopausal 
women may mask the secretion of gonadotropins and subunits by 
these tumors (11,16). Serum LH, FSH, and a-subunit levels were 
low in 7 of the 8 women in this series. However, 6 of these 7 
women had an increased a-subunit/gonadotropin ratio, indicating 
that their LH and FSH levels were more profoundly decreased than 
were a-subunit levels, either as a c~msequence of hypopituitarism 
or as a consequence of a-subunit secretion by the pituitary 
tumor. The latter possibility is favoured, but not proven, by the 
fact that in 4 of 5 women with an elevated serum a-subunit/gona-
dotropin ratio in vivo, a-subunit release in vitro was found. 
Elevated serum gonadotropin and subunit concentrations can 
be used as a tool in the diagnosis of clinically nonfunctioning 
adenomas. In the absence of hypersecretion of other hormones, or 
in the presence of anterior pituitary insufficiency, an elevated 
a-subunit/gonadotropin ratio may prove an additional diagnostic 
tool. In this series, inclusion of an elevated a-subunit/gonado-
tropin ratio as a sign of secretion of a-subunit by a pituitary 
tumor increased the percentage of patients with elevated hormone 
values of some type from 23% to 55%. 
stimulation of gonadotropin and subunit secretion from 
nonfunctioning and gonadotroph pituitary tumors by TRH and GnRH 
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and their suppression by bromocriptine, in vivo as well as in 
vitro, have been reported before (7-16,18,20,23,29,37). We found 
significant responses to TRH in 4 of 7 cultures (57%) in vitro 
and in 13 of 18 patients (72%) in vivo. No relation was found 
between the height of the response to TRH and baseline gonadotro-
pin levels, either in vivo or in vitro. This fact implies that 
the distinction between gonadotroph and nonfunctioning adenomas, 
based on immunocytochemical staining of the tissue or on the 
presence of elevated serum gonadotropin levels in vivo, is absent 
as far as hormone dynamics are concerned. 
Susceptibility to suppression by bromocriptine and stimula-
tion by TRH and GnRH were found to be linked in vitro, suggesting 
that the presence of TRH receptors in adenomatous cells (as 
reported by Peillon et al., 38) is accompanied by the presence 
of GnRH- and dopamine-receptors (as reported by Bevan and Burke, 
39). In vivo, however, this correlation was not confirmed. 
Moreover, 8 of 15 hormone and subunit levels that did not respond 
to TRH or bromocriptine in vivo responded with significant 
changes to these substances in vitro. This discrepancy may result 
from one or more of the following: 1. Most in vitro incubations 
lasted for 48 to 72 hours, whereas in vivo a single dose of an 
agent was administered, resulting in a relatively short expo~ure 
to the effective dose. 2. Not every patient received a placebo, 
but individual reactions to placebo administration varied, so 
significant individual changes may have been missed. In 8 
patients 10 tests were performed. Significant responses of at 
least one hormone or subunit in vitro were mimicked in vivo in 
6 of 7 tests. In the remaining 3 tests, no significant changes 
occurred in any hormone, either in vitro or in vivo. As hormone 
release in vitro could be significantly lowered by bromocriptine 
in 5 out of 8 cultures, this correlation of in vitro and in vivo 
hormone responses may indicate that in more than 50% of the 
patients with a clinically nonfunctioning or gonadotroph 
pituitary adenoma suppression of gonadotropin or subunit levels 
with bromocriptine may be accomplished, especially if administra-
tion of this drug is repeated. 
We conclude that: 1. virtually all clinically nonfunctioning 
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adenomas contain or release gonadotropins or their subunits in 
vitro; 2. in vivo hypersecretion of these hormones and subunits 
occurs infrequently and in this series only in men; 3. an 
elevated ratio of a-subunit to LH and FSH is frequently found in 
women and may prove a useful diagnostic tool; 4. responses to TRH 
and bromocriptine do not depend on baseline gonadotropin levels, 
either in vivo or in vitro, implying that the distinction between 
gonadotroph adenomas and adenomas without hypersecretion of 
gonadotropins in vivo is absent in so far as hormone dynamics are 
concerned. 
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6. ADDITIONAL DATA ON CLINICALLY NONFUNCTIONING AND GONADOTROPH 
PITUITARY ADENOMAS. 
6.1 SIMILARITIES AND DIFFERENCES BETWEEN CLINICALLY NON-
FUNCTIONING AND GONADOTROPH PITUITARY ADENOMAS. 
From chapter 5 it can be concluded that virtually all 
clinically nonfunctioning and gonadotroph pituitary adenomas 
contain or release gonadotropins or gonadotropin subunits in 
vitro. The distinction between gonadotroph and clinically 
nonfunctioning adenomas, based on the presumed absence of 
gonadotropin secretion by clinically nonfunctioning adenomas in 
vivo, is absent under in vitro conditions. Apparently, clinically 
nonfunctioning adenomas produce such small amounts of gonadotro-
pins and gonadotropin subunits, that in vivo serum concentrations 
of these glycoproteins are not elevated. Moreover, adenomatous 
cells that contain or release gonadotropins and subunits in vitro 
may not be recognized as endocrine active cells by histochemistry 
or cytochemistry of the tumor tissue. 
In Table 1 a comparison is made between the outcomes of 
histochemistry, cytochemistry of the isolated cells, and cell 
culture, applied to a number of tumor tissues. TSH was detected 
by cytochemistry in 8 of 13 tumors, but only in 1 could TSH 
production be demonstrated in vitro. This discrepancy is likely 
to be due to a lack in specificity of the TSH antibody used in 
cytochemistry, as in 7 of 8 cases in which TSH production was 
demonstrated by cytochemistry, a-subunit production was found 
during cell-culture. In 7 of 11 cases, gonadotropin production 
by the tumor was demonstrated during cell-culture, but not by 
histochemistry. Cytochemistry of the tumor cells" that were 
isolated for cell-culture, revealed scattered cells which showed 
immunopositivity for LH or FSH in 5 of these 7 tumors. From these 
results, it is clear that isolation of pituitary tumor cells (as 
described in Chapter 5) and measuring hormone concentrations in 
the lysates of these cells is a more sensitive method to 
demonstrate the presence of hormones in the tumor cells than is 
immunohistochemistry. 
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Sex 
M 
M 
M 
M 
M 
M 
M 
M 
M 
M 
F 
F 
F 
F 
F 
F 
Total 
% 
Table 1. Results of immunohistochemistry of the removed tumor 
tissue, immunocytochemistry of isolated tumor cells, and cell 
culture ot these cells from 16 clinically nonfunctioning and 
gonadotroph pituitary adenomas. 
Immunohistochemistry lmmunocytocbemlstry Cell-euHure (tumor tissue) Qsolated cells) 
lH-LH FSH TSH LH FSH TSH subunHs LH FSH TSH ex-subunit 
+ 
+++ ± + + + 
+++ ± + + 
+ +++ + + + 
± ± ± + + + 
± ± ± 
± + + 
± ± ± ± + + + 
+ + + 
± ± + 
+ 
± + + + 
± ± + + + + 
± ± ± + + 
± ± + 
2 3 5 8 8 8 10 13 
18 9 33 31 50 62 50 50 63 6 81 
Number of cells showing immunopositivity: +++: >50%; ++: 20-
50%; +: 10-20%; ±: scattered cells. 
The in vitro production of gonadotropins and their subunits 
is a common feature in both clinically nonfunctioning and 
gonadotroph pituitary adenomas. There are, however, more 
similarities: 
-In both tumortypes hormone or subunit secretion can be 
stimulated by TRH and can be suppressed by bromocriptine, both 
in vivo and in vitro. 
-Both tumortypes are diagnosed in elderly patients. 
-Immunocytochemistry may or may not reveal cells that are 
positive for the gonadotropins or their subunits in both gona-
dotroph and clinically nonfunctioning pituitary adenomas {1-4). 
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LHil 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
9 
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-on electron microscopic examination, there are striking 
differences between the 2 tumortypes. The RER, moderately to 
well developed in gonadotroph adenomas, is poorly developed in 
clinically nonfunctioning adenomas. Secretory granules are more 
numerous in gonadotroph than in clinically nonfunctioning 
adenomas. An abundance of microtubules is observed in gonado-
troph, but not in clinically nonfunctioning pituitary adenomas. 
Both, however, may be shown to consist of cells with secretory 
granules and numerous free ribosomes, while oncocytic transforma-
tion may be observed in both (1,5,6). 
As the similarities are of greater clinical importance than 
the differences, clinically nonfunctioning and gonadotroph 
pituitary adenomas should be regarded as one clinical entity. 
6.2 IN VITRO RESPONSES TO HORMONES AND DRUGS. 
In Chapter 5 the in vitro gonadotropin release from clinically 
nonfunctiong and gonadotroph pituitary adenomas in response to 
TRH, GnRH and bromocriptine was discussed. There were no 
significant differences in intracellular hormone concentrations 
between cells incubated with or without TRH, GnRH or bromocrip-
tine in 2, 4 and 5 tumors, respectively. In one tumor, the 
intracellular concentration of a-subunit, but not of LH, FSH or 
LHB, was significantly elevated after incubation with TRH or 
GnRH. 
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7. AGE-DEPENDENT CHANGES IN SERUM STEROID AND GONADOTROPIN 
CONCENTRATIONS. 
7 • 1 CLUES TO THE ETIOLOGY OF CLINICALLY NONFUNCTIONING AND 
GONADOTROPH PITUITARY ADENOMAS. 
There are indications supporting the hypothesis that primary 
hypogonadism might play a role in the development of gonadotroph 
and clinically nonfunctioning pituitary adenomas: 
-A high incidence of pituitary gonadotroph cell like adenomas 
can be found 15 months or more after gonadectomy in both male and 
female rats (1). 
-In some patients with a gonadotroph adenoma, castration or 
ovarian ablation had been performed decades before the pituitary 
tumor was diagnosed (2-4). 
-Gonadotroph, a-subunit secreting, and clinically nonfunc-
tioning pituitary adenomas occur in elderly patients. Apart from 
adenomas that cause symptoms, subclinical pituitary adenomas 
which do not give rise to any endocrinological abnormalities or 
complaints have been found in 13% of the cases at unselected 
autopsies of men and women over 80 years of age. About 50% of 
these tumors have no immunocytochemical activity (5). In both 
normal men and women, peripheral levels of "free" sex steroids 
decrease with aging. In men there is an age-dependent decrease 
in serum free testosterone concentrations and a moderate increase 
in serum gonadotropin levels (6), while in postmenopausal women 
estrogen concentrations are low and serum gonadotropin levels are 
high. 
On the other hand, the majority of patients with a gonado-
troph, clinically nonfunctioning or a-subunit secreting adenoma 
have a history of normal gonadal function and have children. In 
most men with such pituitary adenomas, a significant rise in 
serum testosterone in response to CG is noted (7), while in 
premenopausal patients ovarian estradiol production may be normal 
or become normal after therapy (8), indicating that primary 
defects in the gonads do not play a role. Also, in aging men a 
moderate age-associated decrease in serum free testosterone 
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concentrations occurs {6), while in postmenopausal women serum 
estrogen concentrations are dramatically low in comparison with 
those in premenopausal women. If hypogonadism were an etiological 
factor in the development of gonadotroph, a-subunit secreting and 
clinically ·non-functioning pituitary adenomas, the incidence of 
these tumors should be higher in women than in men. However, no 
sex-related difference in the incidence of these tumors exists. 
In aging men, an age-associated decrease in plasma free 
testosterone levels is accompanied by an increase in serum 
gonadotropin concentrations {6). By contrast, in postmenopausal 
women circulating sex steroid concentrations do not decrease with 
age, while serum gonadotropin concentrations do decline with age 
{Chapter 7.2). Hormone production by the pituitary gonadotroph 
cells declines in aging postmenopausal women, and increases in 
aging men. Whether this sex-related difference in gonadotroph 
cell activity is reflected in the fact that gonadotroph pituitary 
adenomas are diagnosed for the most part in men is speculative, 
as high serum gonadotropin concentrations that occur normally in 
postmenopausal women may mask the secretion of gonadotropins by 
a gonadotroph pituitary tumor. 
In Chapter 7.2 it is discussed that circulating sex steroid 
concentrations do not influence serum gonadotropin levels in 
postmenopausal women, while hormone production by the pituitary 
gonadotroph cell is less responsive to the administration of 
estradiol . and drugs than in premenopausal women. In old men 
gonadotropin secretion is less influenced by the administration 
of antiopioids than in young men, possibly implicating a 
decreased responsiveness of the pituitary gonadotroph cell to 
GnRH {9). so, compared to young subjects, in both aging men and 
aging women pituitary gonadotroph cell activity is less affected 
by drug administration. Whether these relatively autonomously 
secreting gonadotroph cells which are associated with aging, may 
develop into clinically nonfunctioning or gonadotroph adenoma 
cells, is a tempting speculation. 
In conclusion, hypogonadism is present in both aging men and 
aging women and could play a role in the development of gonado-
troph and clinically nonfunctioning pituitary adenomas. On the 
72 
other hand, relatively autonomously secreting gonadotroph cells 
which are present in aging subjects might develop into clinically 
nonfunctioning or gonadotroph pituitary adenomas, independent of 
circulating sex steroid concentrations. Lastly, a hypothalamic 
cause of the adenomas should be considered. 
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ABSTRACT 
In a group of 680 postmenopausal women participating in a 
population survey we investigated the relationships between serum 
gonadotropin, gonadotropin-subunit and prolactin (PRL) concentra-
tions and age, body mass index (BMI) and levels of sex hormone 
binding globulin (SHBG), estrogens and androstenedione. 
Gonadotropin, a-subunit, and LHB levels were negatively 
correlated with age, while PRL levels did not decrease with age. 
Predicted serum concentrations in women aged 55 and 75 years, 
respectively, decreased for LH from 47.1 to 32.4 IU/L, for FSH 
from 72.1 to 61.6 IU/L, for a-subunit from 2.6 to 1.9 ~g/L, and 
for LHB from 3.2 to 2.4 ~g/L. The ratio of a-subunit to LH and 
FSH decreased and the ratio of LHB to LH increased with age. 
These changes may either be caused by a direct effect of aging 
on pituitary gonadotroph cells or by an effect of aging on the 
hypothalamic regulation of these cells. Serum gonadotropin and 
subunit concentrations were negatively correlated with the BMI, 
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but not with circulating estradiol levels. 
In addition, we found that estrone and estradiol levels were 
positively correlated with the BMI, while circulating levels of 
androstenedione and estrone were more important factors deter-
mining es~rone and estradiol levels, respectively. 
In conclusion: in contrast to what has been reported in normal 
aging men, serum U:l, FSH, a-subunit, and U:IB concentrations 
decrease with age in normal postmenopausal women. 
INTRODUCTION 
In perimenopausal women an increase in serum U:l and FSH 
concentrations occurs in association with a gradual decline in 
ovarian estradiol production. It is well known that in postme-
nopausal women serum U:I, FSH and a-subunit concentrations are 
high in comparison to those in premenopausal women, but whether 
gonadotropin and subunit levels change during the postmenopause 
is not known. 
In aging men, an age-associated decrease in plasma tes-
tosterone levels is accompanied by an increase in serum gona-
dotropin concentrations (1). As estradiol levels in postmeno-
pausal women have been reported to decrease with age (2), an 
associated rise in serum gonadotropin concentrations might be 
expected. On the other hand, the secretion of gonadotropins in 
postmenopausal women seems to be rather insensitive to changes 
in serum estradiol concentrations, as the administration of high 
doses of estradiol does not suppress gonadotropin levels to 
premenopausal values (3,4). 
The aim of the present study was to determine whether aging 
and endogenous plasma androstenedione and estrogen concentrations 
influence serum gonadotropin and subunit levels in postmenopausal 
women. Additionally, we studied the correlations between serum 
androstenedione, estrogen, SHBG and PRL concentrations. 
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SUBJECTS AND METHODS 
Subjects and parameters 
From a large population survey, which took place between 1975 
and 1978 and was designed to study the prevalence and deter-
minants of chronic diseases (5), all female participants 
initially aged 45 to 64 years were selected in 1985 and 1986 for 
a follow-up study (6). Of the initial selection of 1167 women 71 
had died and 87 had moved. Of the remaining 1009 women 855 (85%) 
participated in the follow-up study. 
Age, weight and height were determined, and serum levels of 
LH, FSH, a-subunit, LHB, estrone, estradiol, androstenedione and 
SHBG were measured. A complete dataset was available for 697 
women, of whom 17 were excluded from the analyses, because they 
had estradiol levels above 100 pmoljL. The period since menopause 
in these 680 women was 13.5 ± 7.4 years (range: 1 to 38 years). 
The BMI was calculated as the ratio of weight to square 
height. This is a parameter for the degree of obesity which is 
independent of height (7). 
The a-subunit/gonadotropin ratio was computed by dividing the 
a-subunit level by the sum of LH and FSH levels and multiplying 
the result by 100. 
The LHB/LH ratio was obtained by multiplying the ratio of LHB 
to LH by 100. 
Immunoassays 
Estrone and SHBG levels were measured by radioimmunoassay 
(RIA) as described elsewhere ( 8, 9) . Estradiol and androstenedione 
levels were measured using RIA kits (Diagnostic Products 
Corporation, Los Angeles and Eurodiagnostics, Apeldoorn, The 
Netherlands, respectively). a-Subunit and LHB levels were 
measured by RIA using antibodies from UCB (Brussels, Belgium). 
LH, FSH and PRL levels were measured by radioimmunometric assays 
supplied by IRE-Medgenix (Brussels, Belgium). 
Intra- and interassay coefficients of variation were: <14% 
and <19% for the estrone assay; <12% and <18% for the SHBG assay; 
<15% and <19% for the estradiol assay; <11% and <17% for the 
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androstenedione assay; <6% and <11% for the a-subunit assay; <7% 
and <13% for the LHB assay; <5% and <15% for the LH assay; <3% 
and <8% for the FSH assay; and <7% and <8% for the PRL assay, 
respectively. 
In the gonadotropin and subunit assays crossreactivities on 
a weightjweight basis were: LH assay -FSH 0.5%, a-subunit 0.4%, 
LHB <0.5%; FSH assay -LH and a-subunit 0.06 %, LHB <0.01%; a-
subunit assay -LH 3.9%, FSH 20.0%, LHB 0.2%; LHB assay -LH 
53.4%, FSH 1.1%, and a-subunit 1. 8%. The potencies of the 
preparations used to determine the crossreactivities were 6.6 
IU/~g for LH and 8.7 IUJ~g for FSH. 
Statistics 
Relationships between variables were studied using univariate 
and multivariate linear regression analysis. Multivariate 
regression analysis was applied in order to adjust for inter-
dependency of the variables. Using the number of years after 
menopause or years of age as an independent variable yielded 
virtually the same results. Therefore, in tables and text only 
age has been mentioned as independent variable. 
Multivariate regression analysis was performed including all 
variables and using step-up- and step-down methods (10). As the 
latter methods did not greatly affect the significance of 
outcomes, results obtained using these techniques have not been 
included in tables or text. 
In order to facilitate comparisons between effects of 
variables, standard regression coefficients were used. These 
were computed by multiplying the regression coefficient (b) by 
the SO of the independent variable (x) and dividing the result 
by the so of the dependent variable (y) ( 11) . The standard 
regression coefficient indicates the change in the dependent 
variable, expressed in terms of the SO of that variable, that 
is brought about by a change of 1 SO in the independent variable. 
RESULTS 
Age, BMI, and serum levels of SHBG, gonadotropin-subunits and 
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hormones in the 680 postmenopausal women studied, have been 
summarized in Table 1. 
Table 1. Descriptive and hormonal characteristics of 680 
postmenopausal women. 
Variable Median Mean so Range 
Age (years) 61.4 62.3 5.7 52.9- 76.2 
BMI (kg/h2) 25.9 26.3 3.9 16.5- 47.3 
LH (lUlL) 39.9 41.8 18.0 3.3-162.1 
FSH (IU/L) 67.5 68.3 20.8 9.2-176.8 
ex-subunit (!lfl/L) 2.2 2.3 0.9 0.6- 16.2 
LHP (!lfl/L) 2.7 2.9 1.1 0.5- 9.4 
ex- subunit/ 
gonadotropin ratio(%) 2.1 2.2 0.6 1.1 - 6.5 
LHPfLH ratio(%) 7.0 7.5 2.6 1.4- 46.4 
PRL (!lfl/L) 4.8 6.0 7.3 1.5- 147.9 
Estrone (pmoi/L) 130 138 52 25-353 
Estradiol (pmoi/L) 23 27 20 4- 98 
Androstenedione (nmoi/L) 3.1 3.4 1.9 02- 16.1 
SHBG (nmoi/L) 73.0 80.2 51.3 1.6-416.6 
In Table 2 standard regression coefficients of univariate 
regression equations have been listed. As has been mentioned 
under Subjects and Methods, the standard regression coefficient 
indicates the change in the dependent variable (y), expressed in 
terms of the SD of that variable, that is brought about by a 
change of 1 SD in the independent variable (x). For instance, if 
the variable age changes by one SD, LH levels diminish by 0.23 
SD (see Table 2). The most important factors influencing serum 
gonadotropin and subunit concentrations in postmenopausal women 
are age and the BMI, while PRL levels are positively correlated 
with estradiol levels and age. Estradiol and estrone levels are 
influenced for the most part by estrone and androstenedione 
levels, respectively. 
In Figures 1 to 4 the relationships between age and serum LH, 
FSH, a-subunit, and LHB concentrations are shown. In figures 5 
and 6 the relationships between the BMI and serum FSH concentra-
tions and between estrone and androstenedione levels are 
represented. 
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Table 2. Standard regression coefficients of univariate linear 
regression equations in 680 postmenopausal women. Y denotes 
the dependent, X the independent variable. 
X Age BMI Estrone y Estradiol Androstenedione SHBG 
LH 
-023··· -0.19 ... 
-0.03 
FSH 
-0.14··· 
-0.30··· 
-0.15 ... 
ex-subunit -0.24 ... 
-0.12 ... o.o8· LH~ -0.20 ... -021 ... 
-o.oo 
ex-subunit/ 
O.D1 0.06 O.D1 
-0.03 
-0.03 0.07 
0.06 o.o8· 
-om 
-0.02 0.02 0.08 
gonadotropin ratio 
-o.oa· 0.15 ... 022 ... 
LHWLH ratio 0.16" .. 0.04 0.06 PAL 0.11 .. 
-0.00 0.00 
Estradiol 0.04 021 ... 0.38··· 
Estrone 
-0.02 0.34··· 
Androstenedione 0.02 0.14" .. 
SHBG .0.13 .. -027 ... 
-0.12 .. 
BMI 0.05 
0.10 .. o.o8· 
-o.o9· 
-0.03 
-om 0.06 0.12 •• o.o8· 0.10 .. 
0.25 ... 
-o.o9· 
0.38 ... 0.49 ... 
-0.12 •• 
-om 
-o.o9· 
-om 
*: P<O.OS; **: P<0.01; ***: P<0.001. 
To illustrate the effect of age on serum gonadotropin and 
subunit concentrations, levels of these glycoproteins at 3 age 
levels have been listed in Table 3. Levels stated are predicted 
values from univariate regression analyses; predicted values from 
multivariate regression analyses are virtually the same when mean 
values are substituted for all other entered variables. 
In Table 4 standard regression coefficients of multivariate 
regression equations have been listed. The most striking 
difference between the outcomes of univariate and multivariate 
regression equations is that effects of SHBG levels on several 
variables which were significant when tested univariately, were 
no longer significant in multivariate equations. This is probably 
due to the fact that SHBG levels were very strongly correlated 
with the BMI. It is also apparent that the standard.regression 
coefficients of age and BMI on all variables were not greatly 
affected by introducing more variables into the equations. The 
marginally significant correlations between PRL levels and age, 
serum androstenedione and SHBG concentrations were no longer 
significant when 5 high serum PRL concentrations, ranging from 
37.5 to 147.9 ~g/L, were omitted. 
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Figure 1. Relationship between LH levels and age in 680 
postmenopausal women. The regression line and correlation 
coefficient refer to univariate regression analysis. 
Table 3. Predicted values of gonadotropins and subunits from 
univariate regression analyses in 680 postmenopausal women. 
Age (years) 55 65 75 
LH quJL) 47.1 39.8 32.4 
FSH (IU/L) 72.1 66.8 61.6 
a-Subunit(~g/L) 2.6 2.2 1.9 
LH8 (~g/L) 3.2 2.8 2.4 
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Figure 2. Relationship between FSH levels and age in 680 
postmenopausal women. The regression line and correlation 
coefficient refer to univariate regression analysis. 
DISCUSSION 
The relationships between estrogens, androstenedione, age and 
the BMI or "percent ideal weight" in postmenopausal women have 
been studied by several investigators (2,12-20}. In most of these 
reports, however, only 3 or 4 variables were studied, and the 
numbers of subjects studied were usually small. In this series, 
the number of subjects was large and effects of each variable 
were studied both with and without correction for the influence 
of other variables. To our knowledge, this is the first report 
on the influence of age and other variables on gonadotropin and 
gonadotropin-subunit leveis in postmenopausal women. In the next 
paragraphs the principal relationships will be discussed 
separately. 
81 
6 
4-:. 
·. 
r = -0.24 
p ( 0.001 
a-subunit 
(J.tg/L) 
. . 
.. 
-. . . . . 
.. ·--· -·. ... . . . . - . 
· . 
.. ·. 
. . -- . .. . . .. 
.... .. ··- . - -·- . -
- . ···-· . . . . . ... . . . . 
2~ 
- - . --· . . 
:. ·:-.-.~:: .:_:!:'~:_::;:-_ •• ·=t:.. -~·· =--~-: -~-·;:.:-._:_-
•• :·-. ·:::_:=-- ::.: :.· :·.:. ·=: -· 
- - • ••• •• - •• • • -.- ·- - •• ~.-:-~C.:....-
· . . :::· :.f~ .. ::=:·_=·: ·: .f :-: :.i:: ~:·-::. :. ::·:: .... f. 
0 +-------~-·-·------· 
50 60 70 80 
AGE (YEARS) 
Figure 3. Relationship between a-subunit levels and age in 679 
postmenopausal women. The regression line and correlation 
coefficient refer to univariate regression analysis. one 
extreme a-subunit level (16.2 !Lg/L) was omitted; this scarcely 
changed the slope of the regression line. 
LH. FSH. a-subunit, and LHB levels were negatively correlated 
with age. This effect of age is independent of serum estradiol, 
estrone, androstenedione or SHBG concentrations,. as is clear from 
the multivariate regression analysis. Aging might affect the 
secretory activity of the pituitary gland, but this is unlikely 
as serum PRL concentrations did not decrease with age. Therefore, 
aging may either affect the secretory activity of the pituitary 
gonadotroph cells or may influence the hypothalamic control of 
gonadotropin and subunit secretion, by changing GnRH pulse 
frequency or amplitude in postmenopausal women. This may either 
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Figure 4. Relationship between LH.B levels and age in 680 
postmenopausal women. The regression line and correlation 
coefficient refer to univariate regression analysis. 
be a direct effect of aging on GnRH neurones or an effect on 
factors involved in the regulation of GnRH secretion, such as 
dopamine or opioids. Hypothalamic dopamine levels might decrease 
with age, resulting in lower GnRH levels (21,22,23). If this were 
the case, a positive correlation between PRL levels and age could 
be expected. In this study, however, PRL levels did not increase 
significantly with age when the pathologically high serum PRL 
concentrations of 5 women were omitted, making this explanation 
less likely. The hypothalamic opioid tonus might increase with 
age, while B-endorphin is capable of inhibiting GnRH secretion 
(23). However, GnRH secretion in postmenopausal women seems to 
be rather independent of opioid control, as administration of the 
opiate antagonist naloxone in postmenopausal subjects does not 
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cause an increase in peripheral LH levels (24). Therefore, it 
seems most likely that aging affects the secretory activity of 
either the ~ituitary ~onadotroph cells or of the GnRH neurones. 
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Figure s. Relationship between FSH levels and the BMI in 680 
postmenopausal women. The regression line and correlation 
coefficient refer to univariate regression analysis. 
Gonadotropin 'and subunit levels were negatively correlated 
with the BMI. This relationship is independent of alterations in 
estrogen or SHBG levels correlated with the BMI, as is clear 
from the multivariate regression analysis. LH levels have been 
reported to be low as compared to controls in obese premenopausal 
patients (25,26,27). Increased levels of 8-endorphin in obese 
women (28), resulting in decreased serum gonadotropin concentra-
tions, might cause this phenomenon, but opioid control of 
gonadotropin secretion does not appear very important in 
postmenopausal women, as discussed above. 
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Figure 6. Relationship between estrone levels and andro-
stenedione levels in 680 postmenopausal women. The regression 
line and correlation coefficient refer to univariate regres-
sion analysis. 
Androstenedione levels were weakly correlated with LH levels 
in the multivariate analysis. The reason for this relationship 
is unclear. 
Marginally significant effects of estrone levels on serum FSH 
concentrations were found. The negative correlation between 
estrone and FSH levels may be due to the capacity of brain tissue 
to convert this hormone to estradiol, as has been demonstrated 
in monkey hypothalami (29). It should be emphasized, however, 
that the standard regression coefficient of the relationship 
between serum estrone and FSH concentrations is small, and that 
therefore this relationship does not seem of great importance. 
The a-subunit/gonadotropin ratio was negatively correlated 
with age. This means that a-subunit levels decrease faster with 
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age than the gonadotropin levels. In contrast, the BMI affects 
LH and FSH levels stronger than a-subunit levels. 
Table 4. Standard regression coefficients of multi variate 
linear regression equations in 680 postmenopausal women. Y 
denotes the dependent, X the independent variable. 
X 
y 
Age BMI Estrone Estradiol Androstenedione SHBG 
LH -0.23 ... 
-0.19""" -O.Q3 0.05 0.09" -0.00 
FSH -0.14""" -027""" 
-0.11" 0.06 0.05 O.D1 CL-subunit -0.23""" -0.16""" 0.08 0.05 0.05 -0.00 LH~ -o.2o··· -021""" 0.06 O.D1 0.02 0.05 CL-subunit/ 
gonadotropin ratio -0.07 o.08" 0.19""" 0.02 -0.03 -0.03 
LHWLHratio 0.16""" 0.02 0.15"" -0.06 -0.13"" 0.05 PAL 0.09"a O.D1 -0.08 0.13"" 0.09"a 0.10"a 
Estradiol 0.04 o.o8· 0.31""" 0.09" -0.03 
Estrone -0.05 0.24""" 023""" 0.4o··· 
-0.00 
Androstenedione 0.02 0.13"" 
-0.03 
SHBG 0.14""" -0.26""" -0.01 -O.o3 
-0.02 
•: P<0.05; **: P<0.01; ***: P<0.001. a: trend not significant 
when 5 high serum PRL concentrations (range 37.5 - 147.9 j.!g/L) 
were omitted. 
The LHB/LH ratio, on the other hand, showed a positive 
correlation with age, implying that more free LHB relative to 
LH is secreted with aging. So, as the years progress, a shift 
to more free LHB, LH and FSH relative to a-subunit secretion can 
be shown in postmenopausal women. A positive influence of estrone 
levels on both the a-subunit/gonadotropin ratio and the LHB/LH 
ratio was noticed. This again may represent a negative feedback 
on LH levels of estradiol originating from the conversion of 
estrone in the hypothalamus (29). The negative correlation of the 
LHB/LH ratio with androstenedione levels might be ascribed to the 
positive correlation of LH with this steroid, as discussed above. 
Finally, the absence of a significant negative feedback of 
peripheral estradiol levels on serum gonadotropin and subunit 
concentrations should be discussed. Several explanations may be 
offered: firstly, estradiol levels in postmenopausal women may 
be too low to elicit a response in gonadotropin and subunit 
levels. Secondly, the secretion of gonadotropins in postmenopau-
sal subjects seems to be hard to influence, as the administration 
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of high doses of estradiol does not suppress serum gonadotropin 
concentrations to premenopausal values ( 3, 4) , and the administra-
tion of naloxone to these women does not result in higher LH 
levels (24). Lastly, peripheral levels of estradiol may not 
represent estradiol levels in central nervous tissues: conversion 
of testosterone, androstenedione, and estrone to estradiol by 
these tissues has been reported (29,30,31) and may play a more 
important role in postmenopausal than in premenopausal women, as 
in postmenopausal women peripheral levels of estradiol are low 
in comparison with levels of androstenedione and estrone. 
SHBG levels were negatively correlated with estrone and 
estradiol levels, but these relationships appeared to be due to 
the fact that estrone and estradiol levels were strongly 
correlated with the BMI (r=0.34 and r=0.21, respectively), as 
significance of the correlation between serum SHBG and estrogen 
concentrations was absent when tested in multivariate regression 
analysis. SHBG levels were positively correlated with age. This 
relationship has been reported before (20). Of much more 
importance, however, is the negative correlation with the BMI, 
which also has been reported by others (16,17,25,32,33). 
Abnormalities in hepatic estrogen receptor function have been 
proposed as a mechanism that might explain the negative correla-
tion between SHBG levels and the BMI (34,35). 
Androstenedione levels were shown to increase with the BMI, 
but not with age. Others have reported levels of androstenedione 
to increase with body weight (28,33,36,37). As the conversion 
~ates of androstenedione to other steroids also increase with 
body weight (see below), this fact implies that production rates 
of androgens become higher as the BMI increases. 
Estrone levels were positively correlated with the BMI and 
androstenedione and estradiol levels, and negatively with SHBG 
levels. The significant correlation with SHBG, however, was 
absent when multivariate regression was applied, implying that 
the effect of SHBG levels was confounded by the correlation of 
SHBG levels with other variables. The positive effect of body 
weight on conversion rates of androstenedione to estrone, has 
been reported by several authors (13,14,38). This effect is due 
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to the aromatization of androstenedione in fat tissue (39,40,41). 
The effect of estradiol on estrone levels may represent the 
peripheral conversion of this hormone to estrone, as can be 
observed after administration of exogenous estradiol to postmeno-
pausal women {42,43). The most important factor determining 
estrone levels, however, is the level of circulating andro-
stenedione. Others did not find this correlation {2), but the 
group they studied consisted of only 40 women. Our finding 
implies that the peripheral concentration of the precursor 
hormone, androstenedione, is more important in determining 
estrone levels than is the amount of fat tissue in which the 
conversion takes place. 
Estradiol levels were positively correlated with the BMI, 
estrone and androstenedione levels, and negatively with SHBG 
levels. The latter relationship was absent when tested multi-
variately. The positive correlation of obesity, "percent ideal 
weight", or the BMI with estradiol levels has been reported by 
several authors {2,13,17,25,32). Applying univariate regression 
analysis, we also found a very significant correlation. In 
multivariate analysis, however, the relationship between serum 
estradiol concentrations and the BMI was only marginally 
significant. Of greater importance are the levels of andro-
stenedione and estrone, i.e. the hormones which can be converted 
into estradiol {39). 
Prolactin levels were positively correlated with age and serum 
SHBG, androstenedione and estradiol concentrations. • The sig-
nificance of the first 3 correlations, however, was caused by PRL 
levels ranging from 37.5 to 147.9 ~g/L in 5 women. Some of these 
women may have had symptomless microprolactinomas. Therefore, 
these relationships should be interpreted with caution. Estradiol 
levels were significantly correlated with PRL levels. This 
relationship may be due to interference of estradiol with the 
dopaminergic control of PRL secretion {44). 
In summary, the most important conclusions from the present 
study are that: 1. Serum gonado~ropin, a-subunit, LHB, but not 
PRL concentrations are negatively correlated with age, either 
because of a direct effect of aging on gonadotroph cells or 
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because of an effect of age on the hypothalamic regulation of 
these cells; 2. Gonadotropin and subunit levels are negatively 
correlated with the BMI; 3. Negative feedback of endogenous 
estradiol levels on gonadotropin secretion seems to be absent. 
This may have various causes: a. estradiol levels in postmeno-
pausal subjects may be too low to elicit a response in gonado-
tropin levels; b. secretion of gonadotropins in postmenopausal 
women may be rather autonomous; c. in postmenopausal women, 
conversion of other steroids into estradiol in central nervous 
tissues may play a more important role in regulating the 
gonadotropin secretion than peripheral levels of estradiol; 4. 
Estrone and estradiol levels depend more on androstenedione and 
estrone levels, respectively, than on the BMI. 
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8. EXPERIMENTAL TREATMENTS FOR CLINICALLY NONFUNCTIONING AND 
GONADOTROPH PITUITARY ADENOMAS. 
8.1 GnRH ANALOGS. 
Responses in serum gonadotropin and a-subunit concentrations 
to long-term GnRH analog treatment have been studied extensively 
in patients with prostatic carcinoma or precocious puberty (1-
3). Suppressed serum LH concentrations, suppressed or unaltered 
FSH levels, and elevated a-subunit concentrations have been 
reported (1,3-5). The effect of long-term treatment with GnRH 
analogs on a-subunit production by the pituitary gonadotroph is 
unclear: the amount of a-subunit that is secreted as a part of 
LH or FSH diminishes, while free a-subunit secretion increases. 
FSH and a-subunit are frequently secreted by clinically 
nonfunctioning and gonadotroph pituitary adenomas (6). Moreover, 
gonadotropin and gonadotropin-subunit release from gonadotroph 
and clinically nonfunctioning pituitary adenomas can be stimu-
lated with GnRH, both in vivo and in vitro (6), implying the 
presence of GnRH receptors in these tumors. GnRH analogs might, 
therefore, suppress gonadotropin and subunit release by these 
tumors, which is a prerequisite for any experimental drug 
treatment. 
To elucidate the effect of GnRH analogs on the a-subunit 
production by the pituitary gonadotroph, we studied the effects 
of long-term GnRH analog treatment on serum gonadotropin and a-
subunit concentrations in a group of patients with metastatic 
prostatic carcinoma (Chapter 8.2). 
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8. 2 PROLONGED TREATMENT WITH THE GnRH ANALOG BUSERELIN SUPPRESSES 
LHB PRODUCTION BY THE PITUITARY GONADOTROPH, WHILE a-SUBUNIT 
PRODUCTION DOES NOT CHANGE. 
D.J. Kwekkeboom1 , S.W.J. Lamberts1 , J.H.M. Blom2, F.H. Schroeder2 
and F.H. de Jong1•3 • 
Departments of Medicine1 , Urology2 and Biochemistry3 
Erasmus University Rotterdam, The Netherlands. 
Clinical Endocrinology (Oxf), in press. 
ABSTRACT 
Seven patients with metastatic prostatic cancer were treated 
with biodegradable implants of the GnRH analog buserelin and 6 
were treated with buserelin intranasally. After 4 to 24 weeks of 
treatment mean serum testosterone concentrations were sig-
nificantly lower in the patients treated with implants than in 
those treated intranasally (0. 7 vs. 1. 7 nmol/L respectively; 
P<O.Ol). Also, serum LH concentrations were significantly lower 
in the group treated with implants. 
Serum a-subunit concentrations were significantly higher than 
pre-treatment values during buserelin treatment. However, the sum 
of the concentrations of a-subunit present either as free a-
subunit or as a part of LH did not differ significantly from pre-
treatment values after 8 weeks or more of buserelin treatment. 
During buserelin treatment serum LH concentrations measured 
by radioimmunoassay (RIA) were higher than those measured by 
immunoradiometric assay (IRMA). Crossreactivity of a-subunit in 
the LH RIA accounted for many, but not all of the observed 
discrepancies. 
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We conclude that: 1. The principal long-term effect of 
prolonged buserelin administration on the pituitary gonadotroph 
is the suppression of LHB production, while a-subunit production 
is not affected. 2. The serum concentrations of bioactive LH are 
better reflected by LH concentrations measured by IRMA than by 
those measured by RIA. 3. Subcutaneous application of biodegra-
dable buserelin implants is more effective in suppressing serum 
LH and testosterone concentrations than intranasal buserelin 
application. 
INTRODUCTION 
Repeated administration of GnRH analogs is an effective form 
of androgen suppressing therapy in metastatic prostatic cancer 
(1-10). Buserelin (D-Ser(TBU) 6-GnRH) is a highly active analog of 
GnRH (11). Administered as a nasal spray it produces, after an 
initial increase of serum gonadotropins, a sustained suppression 
of serum LH and testosterone concentrations. 
Recently, we reported on the treatment of prostatic cancer 
with an implant preparation of buserelin and its effects on serum 
testosterone concentrations (12). The aim of the present study 
was to elucidate the differential effect of long-term buserelin 
administration on LH, FSH and a-subunit release from the 
pituitary gonadotroph. We also compared the outcomes of LH 
concentrations during buserelin treatment measured by immunora-
diometric assay (IRMA) with those measured by radioimmunoassay 
(RIA) and related them to circulating a-subunit and testosterone 
concentrations. Additionally, we compared the effects of 
buserelin treatment on serum LH, FSH, a-subunit and testosterone 
concentrations in patients treated with buserelin implants with 
those in patients who received buserelin by means of a nasal 
spray. 
PATIENTS AND METHODS 
Patients and treatment schemes 
Seven patients with histologically proven, advanced prostate 
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cancer {stage c or D) were treated with subcutaneous application 
of buserelin. These patients have been described elsewhere {12). 
After one week of treatment with cyproterone acetate {CPA) {50 
mg 3 times daily), 4 patients received 3.3 mg and the other 3 
received 6.6 mg of buserelin given in a 75:25 polylactide-
glycolide co-polymer formulation by subcutaneous implantation in 
the anterior abdominal wall under local anaesthesia. The 
implantation was repeated every 4 weeks in the patients who 
received a 3.3 mg implant and every 8 weeks in those who received 
a 6.6 mg implant. The treatment with CPA was continued until the 
second implantation of buserelin. 
six other patients with histologically proven, advanced 
prostate cancer {stage Cor D) were treated with 1.5 mg buserelin 
administered subcutaneously for the first 7 days, and thereafter 
with 0.4 mg buserelin three times daily intranasally {i.n.). 
These patients also have been described before {1). 
Immunoassays 
Serum testosterone was measured by RIA as described elsewhere 
{13). The sensitivity of the assay was 0.2 nmoljL; the interassay 
coefficient of variation was <10% for samples containing less 
than 2 nmoljL. 
FSH and LH were measured using IRMA kits supplied by IRE-
Medgenix, Brussels, Belgium. The sensitivity of these assays was 
0.5 IU/L. The crossreactivity of a-subunit in the LH and FSH 
assays expressed in terms of the standard preparations used was, 
respectively, 0.027 and 0.005 IU/~g. LH was also measured by RIA 
using antibodies obtained from KABI {Stockholm, Sweden). The 
sensitivity of this assay was 1.0 IUjL. The crossreactivity of 
a-subunit in this assay was o .152 IU/~g at the 50% binding 
intercept and increased to 0.55 IU/~g at the 90% binding 
intercept. a-Subunit was measured by RIA using antibodies 
purchased from UCB, Brussels, Belgium. The sensitivity of the 
assay was 0.3 ~gjL. The crossreactivities of LH and FSH in the 
a-subunit assay were, respectively, 0.006 and 0.023 ~g/IU. LH, 
FSH and a-subunit were expressed in terms of the MRC 68/40, MRC 
78/549 and MRC 78/556 reference preparations, respectively. The 
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interassay coefficients of variation of the assays were, 
respectively, <14% for LH, <8% for FSH, and <11% for a-subunit. 
Statistics 
Hormone and a-subunit data were evaluated using analysis of 
variance (ANOVA). Log transformation of data was used to 
stabilise variance. For the comparison of treatment means the 
Newman Keuls method was applied (14). P values <0.05 were 
considered significant. 
RESULTS 
There were no significant differences in hormone or a-subunit 
concentrations between patients treated with a buserelin 
implantation every 4 or every 8 weeks. Therefore, the results in 
these two groups were combined. Serum testosterone, LH, FSH and 
a-subunit concentrations in the 7 patients treated with buserelin 
implants are shown in figures 1 to 4. 
CPA significantly suppressed serum testosterone concentrations 
until 2 days after buserelin implantation. The mean serum 
testosterone concentration was lower, but did not differ 
significantly from the pre-treatment mean on days 3 and 5, while 
it was significantly lower from 1 week after buserelin implanta-
tion. After 3 weeks, all testosterone concentrations were lower 
than 1.5 nmoljL, 78% of the testosterone concentrations being 
smaller than or equal to 1. o nmoljL. Serum LH concentrations 
significantly increased during the first 2 days after buserelin 
implantation. After 3 weeks, all LH concentrations except 4 in 
the same patient were undetectable (<0.5 IU/L). Serum FSH 
concentrations only significantly decreased during the second and 
third week after buserelin implantation. 
Serum testosterone concentrations immediately before and after 
any buserelin implantation did not differ significantly, while 
serum FSH, LH and a-subunit concentrations increased significant-
ly only after the first implantation. 
Serum a-subunit concentrations were significantly higher than 
pre-treatment levels during the whole period of buserelin 
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treatment. The amount of a-subunit that is present in LH 
preparations can be estimated to be 6.2% ~gjiU (15). We calcu-
lated the concentration of a-subunit present either as free a-
subunit or in LH by adding 6.2% of the serum LH concentration to 
the serum a-subunit concentration. The concentration of a-subunit 
present as either free a-subunit or as a part of LH significantly 
increased between day 1 and week 4 of treatment, but did not 
differ significantly from pre-treatment values after 8 weeks or 
more of buserelin treatment (Table 1). 
Testosterone 
(nMol/L) 
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Time (weeks) 
Figure 1. Mean (± BE) serum testosterone concentrations in 
patients with prostatic cancer treated with buserelin implants 
(lower symbols;n=7) or with buserelin i.n. (upper symbols; 
n=6). *: P<O.OS **: P<0.01 vs. corresponding group treated 
i.n •• 
Serum LH concentrations measured by RIA, both with and without 
correction for a-subunit crossreacti vi ty, were compared with 
those measured by IRMA (figure 5). In order to make a sound 
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comparison, the detection limit for both assays was set at the 
detection limit of the RIA ( 1. 0 IU/L) • From one week after 
buserelin implantation, LH concentrations measured by RIA 
differed significantly from those measured by IRMA on the 
majority of sampling days. After correction for crossreactivity 
of a.:..subunit in the LH RIA, no significant differences were found 
(Mann-Whitney U-tests). The correlation coefficients between 
serum testosterone concentrations and LH concentrations measured 
by RIA and IRMA were, respectively, 0.61 and 0.73 (Spearman Rank 
Correlation Coefficients; P<0.01 in both instances). After 2 to 
24 weeks of buserelin treatment serum LH concentrations were at 
or below the detection limit in 34 of 36 samples as measured by 
IRMA, but only in 6 of 36 samples as measured by RIA. Serum a-
subunit concentrations were strongly correlated with LH con-
centrations as measured by RIA in these 36 samples (r5 =0. 42; 
P<O.Ol; Spearman Rank correlation test). After correction for a-
subunit crossreactivity, LH concentrations measured by RIA were 
at or below the detection limit in 17 of 36 samples. 
Ui 
(IU/l.) 
100 
30 
20 
TO 
0. 5 
-1 0 1 2 3 4 12 16 20 
Time (weeks) 
Figure 2. Mean (± SE) serum LH concentrations in 7 patients 
with prostatic cancer treated with buserelin implants. • : 
P<O.OS •• : P<0.01 vs. pre-treatment value. 
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Figure 3. Mean (± SE) serum FSH concentrations in 7 patients 
with prostatic cancer treated with buserelin implants. • : 
P<O.OS •• : P<0.01 vs. pre-treatment value. 
Serum LH, FSH, a-subunit and testosterone concentrations in 
the 6 patients treated with buserelin i.n. were compared with 
those in the 7 patients treated with buserelin implants. FSH 
concentrations did not differ significantly at any moment of the 
treatment between the two groups, and a-subunit concentrations 
were lower in the group treated with buserelin implants only 
after the first week of CPA administration (0.6 ~g/L vs. 1.2 
J.Lg/L, respectively; P<O.Ol). As in the group treated with 
implants, serum LH concentrations in the group treated with 
buserelin i.n. were suppressed from week 2 onward. Serum LH 
concentrations from 4 to 24 weeks were undetectable in 9 of 28 
samples in the group receiving buserelin i.n. (range <0.5-3.8 
IU/L), and in 38 of 41 samples in the group treated with 
101 
buserelin implants (range <0.5-0.8 IU/L) (P<0.01; Mann-Whitney 
U-test). Serum testosterone concentrations in both groups are 
shown in figure 1. Mean testosterone concentrations from week 4 
to week 24 were 1.7 ± 0.13 (SE) in the group receiving buserelin 
i.n. and 0~7 ± 0.04 in the group treated with buserelin implants 
(P<O.Ol; Student's t-test). 
a-subunit 
(~g/1) 
o. s 
-I 1 2 3 12 16 20 
Time (weeks) 
Figure 4. Mean (± SE) serum a-subunit concentrations in 7 
patients with prostatic cancer treated with buserelin 
implants. * : P<0.05 •• : P<0.01 vs. pre-treatment value. 
DISCUSSION 
Repeated GnRH analog administration is an effective treatment 
of metastatic prostatic carcinoma (1-10). The effectiveness of 
the treatment, however, may depend on the route of administration 
of the drug. We compared the effects of buserelin administered 
intranasally and as a monthly or two-monthly implant and found 
that the latter 2 methods of application were more effective in 
suppressing serum LH and testosterone concentrations. The same 
has been shown for the depot preparation of another GnRH analog, 
ICI 118630 (Zoladex) (16). As suppression of serum testosterone 
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concentrations is the therapeutic goal of buserelin treatment, 
the administration of this drug by means of subcutaneous 
biodegradable implants is preferable to i.n. application. 
LH 
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Figure 5. Mean serum LH concentrations in patients with 
prostatic cancer treated with buserelin implants. The 
detection limit of both LH assays was set at 1.0 IUJL. 
Ill : LH measured by RIA D : LH measured by RIA after 
correction for crossreactivity of a-subunit • : LH measured 
by IRMA. •: P<O.OS vs. LH IRMA concentrations (Mann-Whitney 
u-test). 
A sustained rise of a-subunit concentrations after prolonged 
GnRH analog treatment has been reported by several groups ( 4, 17) . 
We also found that serum a-subunit concentrations were sig-
nificantly higher than pre-treatment concentrations during the 
whole period of buserelin treatment. The a-subunit secretion from 
the pituitary, however, also depends on the amounts of LH, FSH 
and TSH that are released. As LH concentrations were significant-
ly suppressed after 2 weeks of buserelin treatment, it may be 
questioned whether the a-subunit secretion from this moment was 
increased. We investigated whether the secretion of a-subunit 
from the pituitary gonadotroph was increased by estimating the 
concentrations of a-subunit secreted as either free a-subunit or 
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as a part of LH. After 8 weeks or more of buserelin treatment, 
these concentrations did not differ significantly from pre-
treatment values. Also, FSH concentrations and, therefore, the 
a-subunit concentrations secreted as a part of FSH, did not 
differ significantly from pre-treatment values after 8 weeks or 
more of buserelin treatment. This indicates that prolonged GnRH 
analog treatment does not affect the a-subunit production in the 
pituitary gonadotroph, and that the principal long-term effect 
of this therapy is the suppression of LHB production. Therefore, 
it is not surprising that the administration of GnRH analogs in 
patients with gonadotropin and a-subunit secreting pituitary 
adenomas does not reduce tumoral hormone and subunit secretion, 
as has recently been reported (18,19). 
Table 1. Mean serum concentrations (± SE) of a-subunit present 
as either free a-subunit or as a part of LH in 7 patients with 
prostatic cancer treated with buserelin implants (first 
implant week O); CPA treatment started week -1. 
Time a-Subunit (gg[L} 
Week -1 1.5 ± 0.5 
Day 0 0.9 ± 0.2 
Day 2 3.9 ± 0. s:a 
Week l 2.7 ± 0.3 . 
Week 2 2.8 ± 0.3 
. 
Week 3 2.7 ± 0.3 
Week 4 2.7 ± 0.3 
. 
Week 8 1.9 ± 0.3 
Week 12 2.0 ± 0.3 
Week 16 1.7 ± 0.3 
Week'20 1.7 ± 0.3 
Week 24 1.5 ± 0.3 
* : significantly different from pre-treatment concentration 
a : highest mean concentration 
We found that during buserelin treatment serum LH concentra-
tions measured by IRMA decreased more profoundly than those 
measured by RIA. crossreactivity of a-subunit in the LH RIA 
accounted for the majority of the observed differences. However, 
after correction for crossreactivity of a-subunit, serum LH 
concentrations measured by RIA were higher than those measured 
by IRMA in about 50% of the samples. Other groups have suggested 
that biologically inactive forms of LH that are measured by RIA, 
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but not by IRMA, may be responsible for this discrepancy (4,17). 
Moreover, changes in glycosylation of IJI during GnRH agonist 
therapy have been reported (20) . Serum testosterone concentra-
tions showed a better correlation with IJI concentrations measured 
by IRMA than with LH concentrations measured by RIA. After 2 
weeks or more of buserelin treatment, 78% of the serum tes-
tosterone concentrations were lower than or equal to 1.0 nmol/L 
(castration levels), while 94% of the serum LH concentrations as 
measured by IRMA were at or below the detection limit and the 
majority of LH concentrations as measured by RIA were higher than 
the detection limit. Therefore, the IJI concentrations measured 
by IRMA seem to reflect the concentrations of bioactive LH better 
than those measured by RIA. 
We conclude that: 1. The principal long-term effect of 
prolonged buserelin administration on the pituitary gonadotroph 
is the suppression of IJIB production, while a-subunit production 
is not affected. 2. The serum concentrations of bioactive LH are 
better reflected by LH concentrations measured by IRMA than by 
those measured by RIA. 3. Subcutaneous application of biodegrada-
ble buserelin implants is more effective in suppressing serum IJI 
and testosterone concentrations than intranasal buserelin 
application. 
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8.3 GnRH ANALOGS AND CLINICALLY NONFUNCTIONING AND GONADOTROPH 
PITUITARY ADENOMAS. 
From the preceding chapter it is clear that the production 
of FSH and a-subunit by the pituitary gonadotroph is not 
suppressed by the GnRH analog buserelin. Therefore, it is 
unlikely that the production of FSH and a-subunit, which are 
secreted by the vast majority of clinically nonfunctioning and 
gonadotroph pituitary adenomas in vitro, can be suppressed by 
this drug. 
Not surprisingly, recent reports on the effects of prolonged 
treatment with GnRH agonists in patients with a gonadotroph 
adenoma indicate that serum a-subunit concentrations were higher 
than pre-treatment values, while the response in serum LH and FSH 
concentrations was variable (1,2}. 
Recently, Daniels et al. (3) studied the effects of the GnRH 
agonist buserelin on gonadotropin and subunit secretion from 3 
gonadotroph pituitary adenomas in vitro for 28 days. In all 3 
tumors, a-subunit secretion was stimulated by the GnRH analog 
during the whole period of culturing, while FSH and LH secretion 
were stimulated in 2 and were not significantly different from 
the secretion of untreated cells in the third adenoma~ 
In conclusion, GnRH analog treatment in vivo does not suppress 
a-subunit and FSH production by either the normal pituitary 
gonadotroph or the gonadotroph adenoma cell, and neither does 
GnRH analog treatment suppress gonadotropin and a-subunit 
secretion from gonadotroph adenomas in vitro. For these reasons, 
clinical trials on the effect of buserelin treatment in patients 
with a gonadotroph or clinically nonfunctioning pituitary adenoma 
are not advised. 
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8. 4 DOPAMINE AGONISTS IN THE MANAGEMENT OF CLINICALLY 
NONFUNCTIONING AND GONADOTROPH PITUITARY ADENOMAS. 
INTRODUCTION 
The administration of bromocriptine can lower serum gonado-
tropin and a-subunit concentrations in patients with a gonado-
troph or a-subunit secreting tumor (1-6). Prolonged bromocrip-
tine treatment led to an improvement of visual field defects or 
a reduction in tumor mass in 4 of 6 patients reported in the 
literature (3,5,6). No tumor size reduction was observed after 
the administration of bromocriptine for weeks to several months 
in 26 patients with a clinically nonfunctioning pituitary adenoma 
(7-9). A decrease in tumor size has been reported in 2 such 
patients who were treated with 7.5 mg bromocriptine daily for 4 
months and with 20 mg bromocriptine daily for 25 months, 
respectively (10,11). 
The effectivity of prolonged dopamine agonist treatment in 
patients with a clinically nonfunctioning or gonadotroph 
pituitary tumor may depend on the period of treatment and on the 
administered dose. 
In Chapters 5 and 6 it was reported that bromocriptine can 
lower the in vitro release of gonadotropins and subunits from 
clinically nonfunctioning and gonadotroph pituitary adenomas. 
However, the intracellular hormone concentrations of tumorcells 
incubated with or without bromocriptine for 24 to 72 h did not 
differ significantly. To investigate whether the period of 
treatment with bromocriptine influences the gonadotropin and 
subunit release and intracellular hormone concentrations in these 
tumors in vitro, we culture these tumors for longer periods. The 
preliminary results of 2 of these cultures are presented here. 
To investigate whether prolonged treatment with dopamine 
agonists can lower gonadotropin and subunit secretion from 
clinically nonfunctioning and gonadotroph pituitary adenomas in 
vivo and whether this treatment can lead to tumor size reduction, 
we treat patients with such tumors who do not have major visual 
field defects with the dopamine agonist CV 205-502 for several 
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months. In comparison with bromocriptine, CV 205-502 has a more 
potent and long acting dopaminergic effect on the pituitary (12). 
Also, side effects of bromocriptine which may necessitate the 
discontinuation of the treatment, such as nausea, emesis and 
hypotension, are virtually absent during CV 205-502 treatment 
(13), enabling the administration of high daily doses. 
PATIENTS AND METHODS 
Patients 
In vivo and in vitro responses to hormones and drugs were 
studied in a man with a gonadotroph pituitary adenoma and in a 
woman with a clinically nonfunctioning pituitary adenoma. In both 
the presence of a pituitary tumor was verified by histologic 
examination of the removed tissue. A third patient, a man with 
a clinically nonfunctioning pituitary adenoma, was treated with 
cv 205-502. 
In vivo investigations 
The responses to 200 ~g TRH were studied on seperate days. 
Blood samples were collected before and 10, 20, 30, 60 and 120 
minutes after iv TRH injection. 
Bromocriptine ( 2. 5 mg) or a placebo was given orally and blood 
samples were collected hourly for 12 hours on other days. 
The patient who was treated with CV 205-502 received 75 ~g 
CV 205-502 daily in the first 2 weeks and 150 ~g CV 205-502 in 
the subsequent weeks. 
In vitro investigations 
Surgically removed pituitary tumor tissue was washed several 
times, incubated with dispase, and the cells were dispersed using 
a Dounce type homogenizer. The tumor cells were seperated from 
blood cells by discontinuous Ficoll-Isopaque gradient centrifuga-
tion, and then were suspended in Eagle's Minimum Essential Medium 
(MEM) containing 10% fetal calf serum (FCS) and cultured at 37°C 
in costar Transwell cell culture chambers inserted in Costar 
multiwell plates, at a concentration of 200.000 cells per 
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Transwell. After renewal of the media on day 4 or 5 and on 
subsequent ·days when the media were renewed, the cells were 
incubated in quadruplicate with or without TRH (100 nmoljL; 
Hoechst, Frankfurt am Main, Germany), GnRH (100 nmoljL; Hoechst), 
buserelin (100 nmoljL; Hoechst), or bromocriptine (10 nmoljL; 
Sandoz, Basel, Switzerland). At the end of the incubations, cells 
were lysed in distilled water containing 1 g/L bovine serum 
albumin by repeated freezing and thawing and the hormone 
concentrations in these lysates were measured. 
Immunoassays 
Prolactin and GH were measured using radioimmunoassay (RIA) 
kits obtained, respectively, from IRE-Medgenix, Brussels, 
Belgium, and Sorin, Milano, Italy. TSH was measured using a kit 
obtained from Behring, Marburg, FRG. The sensitivity of the assay 
was 0.1 mU/L and the crossreactivities of subunits and gonadotro-
pins were <1% and <0.01%, respectively. 
FSH and LH were measured using immunoradiometric assay kits 
supplied by IRE-Medgenix, Brussels, Belgium. The sensitivity of 
these assays was 0.5 IU/L. a-Subunit and LHB were measured by RIA 
using antibodies purchased from UCB, Brussels, Belgium. The 
sensitivity of the a-subunit assay was 0.3 ~g/L and that of the 
LHB assay was 1.0 ~g/L. LH was expressed in terms of the MRC 
68/40 reference preparation, FSH in terms of the MRC 78/549 
reference preparation, and a-subunit and LHB in terms of MRC 
78/554 and 78/556, respectively. 
The crossreactivities on a weightjweight basis were: LH assay 
-FSH 0.5%, a-subunit 0.4%, LHB <0.5%; FSH assay -LH and a-subunit 
0.06 %, LHB <0.01%; a-subunit assay -LH 3.9%, FSH 20.0%, LHB 
0. 2%; LHB assay -LH 53.4%, FSH 1.1%, · and a-subunit 1. 8%. The 
potencies of the preparations used to determine crossreactivity 
were for LH 6.6 IU/~g and for FSH 8.7 IU/~g. The intra- and 
interassay coefficients of variation of the assays were, 
respectively, <5% and <15% for LH, <3% and <8% for FSH, <6% and 
<11% for a-subunit, and <7% and <13% for LHB. 
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Statistics 
In vitro hormone release was evaluated using one way analysis 
of variance (ANOVA) • Log transformation of data was used to 
stabilise variance. For the comparison of treatment means the 
Newman Keuls method was applied (14). P values <0.05 were 
considered significant. 
RESULTS 
The patient data and the in vivo hormone levels are presented 
in Table 1. 
Table 1. Patient and hormone data in 3 patients with a 
clinically nonfunctioning or gonadotroph pituitary adenoma. 
a-subunit/ 
Patient Sex Age LH FSH a-subunit LHfl gonadotropin GH PAL TSH T, (lUll) (lUll) (f191L) (f191l-) ratio(%) (f191l-) (f191l-) (mUll) (nmolll) 
M 59 1.3· 16.5. 4.o· <1 22.5" 2.0 42 0.46 95 
2 F 56 4.1· 31.6 1.1· <1· 3.1 22 27.8. 0.72 114 
3 M 57 2.6 7.6 1.0 <1 9.8 <0.5 6.1 2.21 83 
Normal values 
Men 1.9-92 1.6-11.1 0.4-1.1 <1 3.8-16.0 <5 <12 0.2-42 60-140 
Postmenopausal 
women 17.5-86.6 26.2-107.7 1.3-4.0 1.4-5.4 1.4-3.3 <5 <15 0.2-42 60-140 
*: Abnormal concentration. 
A TRH test was performed in patients 1 and 3. In both patients 
the response in TSH levels after TRH administration was normal. 
In response to TRH administration serum LH, FSH, and a-subunit 
concentrations increased by maximally 58%, 4% and 19% in patient 
1, and by 38%, 28% and 56% in patient 3. A normal response to 
metyrapone was present in patients 2 and 3. The effect of 
bromocriptine administration on serum gonadotropin and a-subunit 
concentrations in patients 2 and 3 is shown in figures 1 and 2. 
Serum FSH concentrations decreased during bromocriptine ad-
ministration in both, while serum a-subunit concentrations 
decreased to a lesser extent in patient 3. 
113 
LH 
(IU/L) 
FSH 
35 
( IU/L) 
30 
25 
20 
1.5 
1.2 
a-subunit 0. 9 
(pg/L) 
0. 6 
0. 3 
1 0 11 12 13 H 15 16 17 18 1 9 20 
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Figure 1. Serum gonadotropin and a-subunit concentrations in 
patient 2. A :after administration of a placebo at 800 h. 
e :after administration of bromocriptine (2.5 mg) at 800 h. 
The cultured tumors of both patient 1 and 2 released LH, FSH, 
a-subunit and LHB, while no PRL, GH or TSH could be detected in 
the media or cells. The basal release per 200.000 cellsjday and 
from the the cultured adenoma cells of patient 1 decreased during 
the culture period from 6.3 to 1.6 miU for LH, from 6.3 to 3.0 
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miU for FSH, and from 12.0 to 4.3 ng for a-subunit (Figure 3). 
Because of shortage of medium LHB release could not be evaluated 
on all sampling days. 
LH 
(IU/L)) 
FSH 
(IU/L) 
10 
1.5 
1.3 
a-subunit 1 • 1 
(!Jg/L) 0. 9 
0. 7 
0. 5 
0.3 
0.1 
\ 
9 10 11 12 13 14 15 16 17 1 B 19 20 
Time (hrs) 
\ ,___. 
(wks) 
Figure 2. Serum gonadotropin and a-subunit concentrations in 
patient 3. ..t.. : after placebo; • after bromocriptine ( 2 • 5 
mg, orally) at 800 h. Time in weeks refers to weeks in which 
cv 205-502 was administered. 
The basal release per 200.000 cells/day from the cultured 
adenoma cells of patient 2 decreased during the culture period 
from 2.9 to 1.9 miU for FSH and from 0.9 to 0.4 ng for a-subunit 
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(Figure 4). LHB and LH release could be detected only until the 
7th and 11th day of culturing and have therefore been omitted. 
Bromocriptine inhibited gonadotropin and a-subunit release 
from the adenomatous cells from patient 1 from the 5th day of 
culturing, but not during the first 3 days of incubation {figure 
3). Intracellular hormone or a-subunit concentrations after 12 
days of culturing were not affected by bromocriptine. 
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Figure 3. In vitro effects of bromocriptine on the gonado-
tropin and a-subunit release from the adenoma of patient 1. 
Means (±BE) of quadruplicate incubations are shown. Release 
is per 200.000 cells. o : Control; • : Bromocriptine 10 
nmolfL. 
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Figure 4. In vitro effects of bromocriptine on the gonado-
tropin and a-subunit release from the adenoma of patient 2. 
Means (±SE) of quadruplicate incubations are shown. Release 
is per 200.000 cells. o : Control; • : Bromocriptine 10 
nmoljL. 
TRH, GnRH and buserelin stimulated a-subunit and gonadotropin 
release to a variable extent during the 12 days of culturing 
(data not shown). The percentual release of FSH and a-subunit 
from the tumor from patient 1 decreased significantly as the 
period of incubation with bromocriptine lasted longer (r= -0.86 
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and r= -0.87, respectively; P<O.Ol in both instances), while the 
inhibition of percentual LH release showed no significant time-
dependent trend (r= -0.46). Also, the percentual stimulation of 
FSH and a-subunit release by GnRH increased significantly, while 
no significant time-dependent trend could be demonstrated for the 
effects of TRH or buserelin (data not shown). 
Bromocriptine inhibited FSH and a-subunit release from the 
tumorcells from patient 2 (figure 4). Intracellular FSH and a-
subunit concentrations were significantly decreased after 39 days 
of incubation with bromocriptine. TRH, GnRH and buserelin 
stimulated FSH and a-subunit secretion throughout the 39 days in 
which the cells were cultured (data not shown). The percentual 
release of FSH and a-subunit from the adenoma cells of patient 
2 decreased significantly as the period of incubation with 
bromocriptine lasted longer (r= -0.74 and r= -0.60, respectively; 
P<O.Ol in both instances). Also, as the culture lasted longer, 
the percentual stimulation of FSH and a-subunit release by GnRH 
and buserelin, but not by TRH, increased significantly (data not 
shown). 
The effects of prolonged administration of CV 205-502 on serum 
gonadotropin and a-subunit concentrations in patient 3 are shown 
in figure 2. FSH and a-subunit levels decreased, while serum LH 
concentrations were not greatly affected by the treatment. 
DISCUSSION 
We previously reported that bromocriptine can lower the in 
vitro release of gonadotropins and subunits from clinically 
nonfunctioning and gonadotroph pituitary adenomas. However, the 
intracellular hormone concentrations of tumorcells incubated with 
or without bromocriptine for 24 to 72 h did not differ sig-
nificantly (nonpublished data). The present results indicate 
that it may require long-term culturing with dopamine agonists 
to lower intracellular hormone concentrations in these tumors in 
vitro. 
As cells were cultured longer, an increasing inhibitory action 
of bromocriptine on FSH and a-subunit release from a cultured 
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clinically nonfunctioning adenoma and from a cultured gonadotroph 
pituitary adenoma was found. This effect might be due to an 
inhibitory effect of bromocriptine on cell proliferation. This 
does not seem likely, however, as very few mitoses are observed 
in these adenomas. It is more probable that bromocriptine during 
prolonged incubation has an increasing inhibitory effect on the 
synthesis of gonadotropins and subunits, eventually resulting in 
decreased intracellular concentrations of these glycoproteins. 
From the in vivo tests with bromocriptine in 2 patients with 
a clinically nonfunctioning pituitary adenoma it can be concluded 
that the suppression of serum gonadotropin and a-subunit 
concentrations by this drug is not limited to patients with a 
pituitary adenoma which causes clinically recognizable hyper-
secretion of LH, FSH or a-subunit. 
Prolonged administration of CV 205-502 caused a sustained 
suppression of serum FSH and a-subunit concentrations in a 
patient with a clinically nonfunctioning pituitary adenoma. It 
may be presumed that this is due to a suppressed secretion of FSH 
and a-subunit from the clinically nonfunctioning tumor, as the 
administration of cv 205-502 to normal subjects does not lead to 
appreciable changes in serum gonadotropin concentrations (15). 
The intracellular hormone concentrations in the tumor from 
patient 2 were decreased after prolonged incubation with 
bromocriptine. This might imply that secretory granules and 
intracellular structures involved in the synthesis of glyco-
protein hormones, such as the endoplasmatic reticulum, shrink 
during prolonged bromocriptine treatment. Whether this leads to 
appreciable tumor volume reduction in patients with a clinically 
nonfunctioning or gonadotroph pituitary adenoma during treatment 
with CV 205-502 in vivo, is the subject of a study that has only 
just started. 
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9. DISCUSSION OF THE MAJOR CONCLUSIONS. 
The clinical classification of pituitary adenomas according 
to the hormones which they hypersecrete in vivo distinguishes 
gonadotroph from clinically nonfunctioning adenomas. Yet in 
postmenopausal women most pituitary tumors which have the 
immunocytochemical and ultratstructural features of gonadotroph 
adenomas do not cause elevated serum gonadotropin concentrations 
(1). These tumors obviously are not clinically recognized as 
gonadotroph adenomas because of the high serum gonadotropin 
concentrations that occur normally in postmenopausal women. The 
classification of pituitary adenomas according to immunocyto-
chemical and ultrastructural features also distinguishes between 
nonfunctioning and gonadotroph adenomas. Yet both gonadotroph and 
virtually all nonfunctioning pituitary adenomas contain and 
release gonadotropins or their subunits in vitro (Chapter 5). 
Apparently, clinically nonfunctioning pituitary adenomas contain 
and secrete such small amounts of gonadotropins and gonadotropin-
subunits, that tumorcells do not immunostain and that in vivo 
serum concentrations of these glycoproteins are not elevated. 
The in vitro production of gonadotropins and their subunits 
is a common feature in both clinically nonfunctioning and gonado-
troph pituitary adenomas. There are, however, more similarities: 
-In both tumortypes hormone or subunit secretion can be 
stimulated by TRH and can be suppressed by bromocriptine, both 
in vivo and in vitro (Chapters 5 and 8.4). 
-Both tumortypes are diagnosed in elderly patients. 
-Immunocytochemistry may or may not reveal cells that are 
positive for the gonadotropins or their subunits in both 
gonadotroph and clinically nonfunctioning pituitary adenomas (1-
4). 
-on electron microscopic examination, there are striking 
differences between the 2 tumor types. The RER, moderately to 
well developed in gonadotroph adenomas, is poorly developed in 
clinically nonfunctioning adenomas. Secretory granules are more 
numerous in gonadotroph than in clinically nonfunctioning 
adenomas. An abundance of microtubules is observed in ganado-
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troph, but not in clinically nonfunctioning pituitary adenomas. 
Both, however, may be shown to consist of cells with secretory 
granules and numerous free ribosomes, while oncocytic transforma-
tion may be observed in both {1,5,6). 
As the similarities are of greater clinical importance than 
the differences, clinically nonfunctioning and gonadotroph 
pituitary adenomas should be regarded as one clinical entity. 
The etiology of clinically nonfunctioning and gonadotroph 
pituitary adenomas is unclear. There are, however, indications 
that primary hypogonadism might play a role in the development 
of these tumors: 
In aging men, an age-associated decrease in plasma tes-
tosterone levels is accompanied by an increase in serum gonado-
tropin concentrations (7). By contrast, in aging postmenopausal 
women circulating sex steroid concentrations do not decrease, 
while serum gonadotropin concentrations decline with age (Chapter 
7.2). In men gradual age-dependent hypogonadism develops, while 
in postmenopausal women age-independent hypogonadism is present. 
Hormone production by the pituitary gonadotroph cells declines 
in aging postmenopausal women, and increases in aging men. 
Whether this sex-related difference in gonadotroph cell activity 
is reflected in the fact that gonadotroph pituitary adenomas are 
diagnosed for the most part in men is speculative, as high serum 
gonadotropin concentrations that occur normally in postmenopausal 
women may mask the secretion of gonadotropins by a gonadotroph 
pituitary tumor. 
Circulating sex steroid concentrations do not influence serum 
gonadotropin levels in postmenopausal women (Chapter 7.2), while 
hormone production by the pituitary gonadotroph cell is less 
responsive to the administration of estradiol and drugs than in 
premenopausal women. In old men gonadotropin secretion is less 
influenced by the administration of antiopioids than in young men 
(8). So, compared to young subjects, in both aging men and aging 
women pituitary gonadotroph cell activity is less affected by 
drug administration. Whether these relatively autonomously 
secreting gonadotroph cells which are associated with aging, may 
develop into clinically nonfunctioning or gonadotroph adenoma 
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cells, is a tempting speculation. 
In conclusion, hypogonadism is present in both aging men and 
aging women and could play a role in the development of gonado-
troph and clinically nonfunctioning pituitary adenomas. On the 
other hand, relatively autonomously secreting gonadotroph cells 
which are present in aging subjects might develop into clinically 
nonfunctioning or gonadotroph pituitary adenomas, independent of 
circulating sex steroid concentrations. Lastly, a hypothalamic 
cause of these adenomas should be considered. 
The accepted therapy of clinically nonfunctioning and 
gonadotroph pituitary adenomas is transsphenoidal adenomectomy. 
Because of operative and postoperative complications, medicinal 
therapy also receives attention. A prerequisite for any drug 
therapy is tumor volume reduction. Therefore, hormone secretion 
by the tumor should decrease, whether caused by a reduction in 
the number of cells or by a decreased tumorcell volume. As 
gonadotroph and virtually all clinically nonfunctioning pituitary 
adenomas produce IJI, FSH, a-subunit, IJIB or a combination of 
these, it is essential that any drug to be administered suppres-
ses the production of these hormones and subunits. 
GnRH agonists can suppress IJI production by the gonadotroph 
cells. In men with prostatic carcinoma, however, prolonged 
treatment with these drugs does not suppress the production of 
a-subunit or FSH (Chapter 8. 2) • Neither can GnRH agonists 
suppress the production of a-subunit or FSH from gonadotroph or 
clinically nonfunctioning adenomas, either in vivo or in vitro 
(9). For these reasons, trials on the effect of GnRH agonists in 
patients with a clinically nonfunctioning or gonadotroph 
pituitary adenoma are not recommended. 
During long-term culturing the suppressive effect of the 
dopamine agonist bromocriptine on gonadotropin and subunit 
secretion from cells from clinically nonfunctioning or gonado-
troph pituitary adenomas increases as incubations last longer 
(Chapter 8.4). Intracellular hormone concentrations in cultured 
cells from a clinically nonfunctioning adenoma were decreased 
after several weeks of incubation with bromocriptine. Preliminary 
results on the effect of prolonged treatment with a dopamine 
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agonist in a patient with a clinically nonfunctioning pituitary 
adenoma who was not operated on, show a decreased secretion of 
FSH and a-subunit. Whether this suppressive effect on the 
secretion and synthesis of gonadotropins and a-subunit leads to 
appreciable tumor volume reduction has yet to be seen. 
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SUMMARY 
In comparison with other types of pituitary tumors clinical-
ly nonfunctioning and gonadotroph pituitary adenomas are 
diagnosed in elderly patients. In most cases they cause visual 
complaints (Chapter 3). Gonadotroph adenomas are characterized 
by elevated serum concentrations of FSH or, occasionally, of LH. 
Clinically nonfunctioning pituitary adenomas are characterized 
by the absence of hypersecretion of any pituitary hormone in 
vivo. 
Cultured cells from gonadotroph and virtually all clinically 
nonfunctioning adenomas produce and contain FSH, LH, or the 
subunits of these hormones, alone or in combination (Chapter 5). 
The secretion of these hormones and subunits from both clinically 
nonfunctioning and gonadotroph pituitary adenomas can be 
stimulated by GnRH and TRH and can be suppressed by bromocrip-
tine, both in vivo and in vitro (Chapter 5). As the similarities 
between both tumortypes are of greater clinical importance than 
the differences, clinically nonfunctioning and gonadotroph 
pituitary adenomas should be regarded as one clinical entity. 
The etiology of clinically nonfunctioning and gonadotroph 
pituitary adenomas is unclear. There are, however, indications 
that primary hypogonadism might play a role in the development 
of these tumors. Hypogonadism is present in postmenopausal women 
and in aging men. On the other hand, serum gonadotropin con-
centrations in postmenopausal women are not influenced by 
circulating endogenous estradiol levels (Chapter 7. 2) , and, 
compared to young subjects, the pituitary gonadotroph cell 
activity is less affected by drug administration in both aging 
men and aging women. These relatively autonomously secreting 
gonadotroph cells which are associated with aging might develop 
into clinically nonfunctioning or gonadotroph adenomas, indepen-
dent of circulating sex steroid levels. Lastly, a hypothalamic 
cause of these tumors should be considered. 
The accepted therapy of clinically nonfunctioning and 
gonadotroph pituitary adenomas is transsphenoidal adenomectomy. 
Because of operative and postoperative complications, medicinal 
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therapy also receives attention. A prerequisite for any drug 
therapy is tumor volume reduction. Therefore, hormone secretion 
by the tumor should decrease, whether caused by a reduction in 
the number of cells or by a decreased tumorcell volume. As 
gonadotroph and virtually all clinically nonfunctioning pituitary 
adenomas produce LH, FSH, a-subunit, LHB or a combination of 
these, it is essential that any drug to be administered suppres-
ses the production of these hormones and subunits. 
GnRH agonists can suppress LH production by the gonadotroph 
cells. In men with prostatic carcinoma, however, prolonged 
treatment with these drugs does not suppress the production of 
a-subunit or FSH (Chapter 8.2). Neither can GnRH agonists 
suppress the production of a-subunit or FSH from gonadotroph or 
clinically nonfunctioning adenomas, either in vivo or in vitro. 
For these reasons, GnRH agonist treatment in patients with a 
clinically nonfunctioning or gonadotroph pituitary adenoma is not 
recommended. 
During long-term culturing the suppressive effect of the 
dopamine agonist bromocriptine on gonadotropin and subunit 
secretion from cells from clinically nonfunctioning or gonado-
troph pituitary adenomas increases as incubations last longer 
(Chapter 8.4). Intracellular hormone concentrations in cultured 
cells from a clinically nonfunctioning adenoma were decreased 
after several weeks of incubation with bromocriptine. Preliminary 
results on the effect of prolonged treatment with a dopamine 
agonist in a patient with a clinically nonfunctioning pituitary 
adenoma who was not operated on, show a decreased secretion of 
FSH and a-subunit. Whether this suppressive effect on the 
secretion and synthesis of gonadotropins and a-subunit leads to 
appreciable tumor volume reduction has yet to be seen. 
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SAMENVATTING 
Klinisch niet-functionerende en gonadotrofe hypofyseadenomen 
komen in vergelijking met andere hypofysetumoren voor bij oudere 
patienten en veroorzaken in het merendeel van de gevallen 
visusklachten (Hoofdstuk 3). Gonadotrofe hypofyseadenomen zijn 
klinisch te herkennen aan verhoogde bloedspiegels van FSH en soms 
LH. Klinisch niet-functionerende hypofyseadenomen kenmerken zich 
door de afwezigheid van hypersecretie van enig hypofys~voorkwabs­
hormoon in vivo. 
In kweek gebrachte cellen van gonadotrofe en vrijwel alle 
klinisch niet-functionerende hypofyseadenomen produceren en 
bevatten FSH, LH, of de subunits van deze hormonen, afzonderlijk 
of in combinatie {Hoofdstuk 5). De secretie van deze hormonen en 
subunits door zowel klinisch niet-functionerende als gonadotrofe 
hypofyseadenomen kan in vivo en in vitro gestimuleerd worden met 
GnRH en TRH en geremd worden met bromocriptine (Hoofdstuk 5). 
Aangezien de overeenkomsten tussen beide tumortypen van grater 
klinisch belang zijn dan de verschillen, moeten klinisch niet-
functionerende en gonadotrofe hypofyseadenomen als een klinische 
groep beschouwd worden. 
De etiologie van klinisch niet-functionerende en gonadotrofe 
hypofyseadenomen is onduidelijk. Er zijn echter aanwijzingen dat 
primair hypogonadisme een rol kan spelen bij het ontstaan van 
deze tumoren. Hypogonadisme is aanwezig bij postmenopausale 
vrouwen en bij oudere mannen. Anderzijds worden de gonadotrofine 
spiegels bij postmenopausale vrouwen niet beinvloed door endogene 
plasma oestradiol spiegels (Hoofdstuk 7. 2) , en vertonen de 
gonadotrofine spiegels bij zowel oudere mannen als oudere vrouwen 
een kleinere respons op toediening van medicamenten dan bij jonge 
personen. De relatief autonoom secernerende gonadotrofe hypofyse-
cellen die bij verouderende mannen en vrouwen aanwezig zijn, 
zouden zich kunnen ontwikkelen tot gonadotrofe of klinisch niet-
functionerende hypofyseadenomen, onafhankelijk van circulerende 
spiegels van geslachtssteroiden. Een hypothalame oorzaak van deze 
tumoren kan evenmin worden uitgesloten. 
De gangbare therapie voor klinisch niet-functionerende en 
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gonadotrofe hypofyseadenomen is transsphenoidale adenomectomie. 
Gezien het operatierisico en postoperatieve complicaties, staat 
medicamenteuze therapie in de belangstelling. Aangezien gonado-
trofe en vrijwel alle klinisch niet-functionerende hypofyseadeno-
men LH, FSH, a-subunit, LHB, of een combinatie van deze glycopro-
teinen produceren, is een primaire eis voor een toe te passen 
medicament dat het de productie van deze hormonen en subunits 
remt. De aan een dergelijke therapie te stellen eis is immers dat 
ze tumorvolume reductie veroorzaakt; of dit nu door een ver-
mindering van het celaantal of van het celvolume tot stand komt, 
in beide gevallen zal de hormoonsecretie minder worden. 
GnRH agonisten kunnen de productie van LH door de gonadotrofe 
cellen remmen. Bij mannen met prostaatcarcinoom leidt langdurige 
behandeling met deze geneesmiddelen echter niet tot een ver-
minderde productie van a-subunit of FSH (Hoofdstuk 8.2). Evenmin 
verminderen GnRH agonisten de productie van a-subunit of FSH door 
gonadotrofe of klinisch niet-functionerende hypofyseadenomen in 
vivo of in vitro. Om deze redenen is de behandeling van klinisch 
niet-functionerende en gonadotrofe hypofyseadenomen met GnRH 
agonisten niet geindiceerd. 
De dopamine agonist bromocriptine remt de secretie van 
gonadotrofines en subunits in vitro bij de meerderheid van 
klinisch niet-functionerende en gonadotrofe hypofyseadenomen. 
Tijdens langdurige incubatie van adenoomcellen met bromocriptine 
neemt het remmend effect van dit geneesmiddel op de gonadotrofi-
ne- en a-subunit secretie toe (Hoofdstuk 8.4). Incubatie van 
gekweekte cellen van een kliniscn niet-functionerend adenoom met 
bromocriptine gedurende meerdere weken leidde tevens tot 
vermindering van de intracellulaire hormoonconcentraties. De 
voorlopige gegevens omtrent de langdurige behandeling met een 
dopamine agonist van een niet geopereerde patient met een 
klinisch niet-functionerend hypofyseadenoom tonen remming van de 
FSH en a-subunit secretie. Of dit remmend effect op de secretie 
en de synthese van gonadotrofines en subunits gepaard gaat met 
tumorvolume reductie, moet worden afgewacht. 
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ACTH 
AN OVA 
b 
BMI 
BSA 
CG 
CPA 
CT scan 
cv 
Et al. 
F 
FCS 
FRG 
FSH 
g 
GH 
GnRH 
h 
i.e. 
i.n. 
IRMA 
IU 
iv 
kg 
L 
LH 
M 
HEM 
mg 
miU 
mL 
MRC 
mu 
ng 
nmol 
LIST OF ABBREVIATIONS 
Adrenocorticotroph hormone 
Analysis of variance 
Slope 
Body mass index 
Bovine serum albumin 
Chorionic gonadotropin 
Cyproterone acetate 
Computer(ized) tomographic scan 
Coefficient of variation 
And others 
Female 
Fetal calf serum 
Federal republic of Germany 
Follicle stimulating hormone 
Gram 
Growth hormone 
Gonadotropin releasing hormone 
Hour(s); (height) 
That is 
Intranasal(ly) 
Immunoradiometric assay 
International unit 
Intravenous(ly) 
Kilogram 
Liter 
Luteinizing hormone 
Male 
Minimum essential medium 
Milligram 
Milli international unit 
Milliliter 
Medical research council 
Milli unit 
Nanogram 
Nanomol 
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p 
PAS 
pmol 
PRL 
r 
rs 
RER 
RIA 
SD 
SE 
SHBG 
T 
T4 
TRH 
TSH 
u 
vs. 
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Probability 
Perjodic acid Schiff 
Picomol 
Prolactin 
Correlation coefficient 
Spearman rank correlation coefficient 
Rough endoplasmatic reticulum 
Radioimmunoassay 
Standard deviation 
Standard error of the mean 
Sex hormone binding globulin 
Testosterone 
Thyroxine 
Thyrotropin releasing hormone 
Thyroid stimulating hormone 
Unit 
Versus 
Microgram 
Degrees Celsius 
1970-1976 
1976-1985 
1985 
1986-1989 
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